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1 Introduction 
1.1 Psychoneuroimmunology 
Psychoneuroimmunology (PNI) is the investigation of the interaction between neu-
roendocrine and neural functions, behavior, and immune processes, which has 
been established as an interdisciplinary field in the late 1970s. Over the past 30 
years it has become evident that these systems influence each other reciprocally 
(Ader, 2000). Neuroendocrine mediators released by the pituitary gland (Kelley et 
al., 1985) as well as the sympathetic division of the autonomic nervous system 
affect immune cell activity. Contrarily, products of the immune system such as 
hormones and cytokines, influence both neuroendocrine and neural activities. Evi-
dence for this has been provided as early as 1975, where plasma concentration of 
glucocorticoids rose during a specific immune response, indicating that compo-
nents of the immune system are able to influence the nervous- and hormonal sys-
tem (Besedovsky et al., 1975). In addition, PNI research also elucidated the ef-
fects of behavioral processes on the neuroendocrine and immune system and vice 
versa. Stressful life events (Glaser and Kiecolt-Glaser, 2005) have been shown to 
affect cellular immune und humoral responses, as well as disease development, 
while immune responses demonstrated an influence on behavior and affective 
state (Maier and Watkins, 1998; Miller et al., 2009) (Figure 1). 
This multi-directional communication is possible because cells of the immune sys-
tem express receptors for hormones and neurotransmitters (Blalock and Smith, 
2007) and hormones in turn can influence the regulation of an immune response 
and affect processes of the central nervous system (CNS) (Yirmiya and Goshen, 
2011). Furthermore, receptors for cytokines and prostaglandins have been found 
on glial and neuron cells (Blalock and Smith, 2007) and the CNS can influence 
immunity through the release of cortisol from the hypothalamus-pituitary-adrenal 
axis (HPA-axis), which functions as a humoral pathway of the CNS (Viveros-
Paredes et al., 2006) (Figure 1).  
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Fig. 1: Bidirectional communication between the CNS, the neuroendocrine, the peripheral im-
mune system and behavioral processes 
Neuroendocrine agents and autonomic processes of the nervous system can influence immune activity, 
whereas components of the immune system are able to influence the nervous- and hormonal system. Stress 
experience can affect cellular immune und humoral responses and immune responses in turn can influence 
behavior and affective state. The CNS and the immune system are connected through afferent and efferent 
pathways. Sensory fibers of the vagus nerve serve as an afferent and efferent neural route of communication. 
In addition, messengers such as cytokines operate on the humoral afferent route and can reach the brain 
through circumventricluar organs. Another major efferent route comprises the sympathetic nervous system, 
which is directly connected with primary and secondary lymphoid organs. In addition, the HPA-axis also func-
tions as a connection pathway between these systems. Modified from (Glaser and Kiecolt-Glaser, 2005). 
Unambiguous evidence of the functional interactions between the CNS, behavior, 
the neuroendocrine and immune systems is derived from immune conditioning 
(Schedlowski and Pacheco-López, 2010). Here, the mechanisms of classical con-
ditioning of immune functions offer an elegant way to unravel the communication 
network between these systems. 
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1.1.1 Classical conditioning of immune functions 
Classical conditioning can be defined as learning between causal and temporal 
relations of internal and external stimuli. This enables the organism to access and 
choose the appropriate response set before significant biological events occur. 
Ivan Pavlov initially described this paradigm, eventually leading to studies of 
learned placebo responses, in which immunobiological processes are modified 
through behavioral conditioning (Pavlov, 1927). In short, during a behavioral condi-
tioning paradigm, there are two distinct processes involved, the first of which is a 
learning phase (acquisition). Here, a novel stimulus, such as an inert pill (placebo), 
an odor, or a flavor (conditioned stimulus, CS) is given paired with a substance, 
which induces physiological changes (unconditioned stimulus, US). Following re-
peated pairings, is a memory phase (evocation), in which the CS is represented 
alone in order to elicit a behavioral and/or a physiological response (conditioned 
response, CR), which mimics the effect of the US. As a result, the characteristics 
of a biologically important stimulus (US) are transmitted to another stimulus with-
out these characteristics (CS). 
Based on the pioneering studies of classical conditioning of the immune system 
(Ader and Cohen, 1993), a conditioned taste aversion (CTA) paradigm within rats 
has been developed. Here, saccharin, a novel tasting stimulus is utilized as a CS 
while the potent immunosuppressive drug, cyclosporine A (CsA) acts as an US 
during the acquisition phase (Exton et al., 2002; Wirth et al., 2011). CsA is widely 
used in organ transplantation to prevent rejection and within treatment of chronic 
inflammatory autoimmune diseases (Kapturczak et al., 2004), when a suppression 
of immune functions, particularly T cell activity, is needed (see section 2.2). Sub-
sequently, during the evocation phase, the CS is represented alone and induces 
behavioral (taste aversion) and immunological changes, which mimic the effects of 
CsA (US). Further animal studies provided impressive evidence of successful im-
plementation of this conditioning paradigm. In the context of supportive therapies 
within organ transplantation and chronic inflammatory autoimmune diseases, both 
mortality rates and disease symptoms were reduced (Schedlowski and Pacheco-
López, 2010). Eventually, this taste-immune conditioning paradigm was estab-
lished within humans and has been shown to induce a learned immunosuppres-
sion (Goebel et al., 2002). Here, a novel tasting drink (CS) is repeatedly paired 
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with CsA (US) during the acquisition phase. When the CS is represented alone 
during the evocation phase, it elicits a significant suppression of T cell activity, 
thereby resembling the effects of CsA (Goebel et al., 2002).  
Conditioning procedures with pharmacological agents can create memory traces 
of the learned responses and consequently be recalled in the future (Amanzio and 
Benedetti, 1999), which offers the possibility of implementing these paradigms 
within a clinical context as a supportive therapy. Studies within animals and hu-
mans have shown that the higher the number of learning trials during the acquisi-
tion phase, the stronger the placebo response during evocation (Albring et al., 
2012; Niemi et al., 2007). The learned immunosuppression described above can 
also be elicited after a second sole presentation of the CS (Wirth et al., 2011), 
where psychological and biological variables, such as state anxiety and plasma 
noradrenaline concentrations, predicted the learned immunosuppression before 
the CS re-exposition during evocation (Ober et al., 2012). Furthermore, just like 
any other learning process, the learned immunosuppression is subject to extinc-
tion over time, where the learned behavior continuously recedes. In order to inte-
grate learned immune responses as a supportive therapy within a clinical context, 
it is essential that this receding process is inhibited. This has already been suc-
cessfully done within experimental animals (Exton et al., 1999) and recently, the 
extinction process was counteracted in a study with healthy males, which received 
a subtherapeutic dose of CsA paired with the CS during the evocation phase 
(Albring et al., 2014). 
Besides the potential therapeutic relevance, the paradigm of behavioral condi-
tioned immunosuppression can also be utilized to elucidate afferent, efferent and 
central mechanisms steering the learned immune response. 
1.1.2 Mechanisms and pathways of the behavioral conditioned immune 
response 
During acquisition, the brain must be able to detect and associate the sensory 
characteristics of the CS, as well as the alterations within the immune system in-
duced through the US. Additionally, the immune system needs to sense these al-
terations and be able to communicate its peripheral response through a shared 
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chemical language to the nervous system (Blalock and Smith, 2007). This is only 
possible by means of a link between the brain and immune system via afferent 
and efferent pathways.  
To date, the afferent mechanisms through which the brain detects immunosup-
pressants, such as CsA, are poorly understood, although first evidence indicates 
that CsA may exert its influences on the brain through a direct mechanism 
(Pacheco-López et al., 2012). The afferent immune-to-brain signaling comprises 
humoral and neuronal pathways. The systemic or humoral pathway, through which 
messengers such as cytokines and prostaglandins reach the brain via cerebral 
vasculature or circumventricluar organs (reviewed in Quan and Banks, 2007) and 
the neuronal or hardwired signaling pathway, which transforms peripheral immu-
nological changes directly into neurological activity. This has been demonstrated 
through alterations in EEG-activity, increased noradrenaline levels, cytokine mes-
senger ribonucleic acid (mRNA) expression and through induction of the neuronal 
activity marker c-fos (Engler et al., 2011). The vagus nerve serves as a neural 
route of communication between the immune system and the CNS (Goehler et al., 
2000) while the effects of immunomodulators, which can induce autonomic reflex-
es and behavioral responses can be inhibited or even blunted through vagotomy 
(Fleshner et al., 1998). However, within the paradigm of behavioral conditioning of 
immune responses, utilizing CsA as an US, the vagus nerve did not seem to be 
involved within the afferent pathway, as its deafferentation did not prevent the 
conditioning process (Pacheco-López and Bermúdez-Rattoni, 2011). 
One major efferent neural pathway linking the brain with the immune system is the 
sympathetic nervous system (Nance and Sanders, 2007). It is directly connected 
with primary and secondary lymphoid organs (Bermúdez-Rattoni, 2004) through 
sympathetic nerve fibers that have been shown to regulate the immune system 
through the neurotransmitter noradrenaline (Sanders and Straub, 2002). Within 
the CTA paradigm, where CsA is utilized as an US, it was repeatedly demonstrat-
ed that conditioned suppression of TH1 cytokine production and lymphocyte prolif-
eration was mediated through the splenic nerve, noradrenaline and adrenoceptor-
dependent mechanisms (Exton et al., 2002). Nonetheless, the splenic nerve ap-
pears to be one of many efferent neural routes which are mobilized during learned 
immunosuppression (Exton et al., 2000). Recently, utilizing the CsA-saccharine 
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conditioning paradigm within rodents, the enzymatic activity of calcineurin (CaN) 
has been reduced through the immunosuppressive conditioning procedure via a β-
receptor dependent mechanism (Pacheco-López et al., 2009). This finding is 
noteworthy, as the CR appears to transform the same sub-cellular components of 
CaN as the pharmacologic effects of CsA, but through a different route.  
A humoral efferent pathway, comprising the HPA-axis and elevated glucocorticoid 
levels has also been proposed as being responsible for behaviorally conditioned 
immunosuppression. This appears to be unlikely, as studies reported no difference 
in corticosterone (cortisol in humans, respectively) levels in either animal or hu-
mans in both control and experimental groups (Niemi et al., 2007; Wirth et al., 
2011). In conclusion, studying behaviorally conditioned immunosuppression para-
digms is an elegant way to elucidate neuro-immune communication by only em-
ploying a single model and current research is dedicated to unravel the underlying 
mechanisms and signaling pathways, as well as utilizing these findings for thera-
peutical purposes. Here, placebo and nocebo effects have been shown to affect 
behavioral processes, the neurochemistry of the CNS and subsequently the pe-
riphery of the body and medical treatment outcomes. 
1.2 The placebo and nocebo effect 
Placebo effects are positive physiological responses following sham treatments, 
which cannot only be elicited through drugs, containing inactive substances, but 
also through a wide range of interventions (Pacheco-López et al., 2006). The term 
placebo originates from the 13th century and used to be considered a fraud. It was 
not until the middle of the 20th century that the relevance of the placebo was rec-
ognized as a positive influence in the treatment of various diseases (Beecher, 
1955). However, to this date the definition of the placebo effect remains controver-
sial and from an evolutionary perspective it remains unclear, why placebo effects 
have developed at all (Sullivan et al., 2010). 
The concept of the nocebo effect evolved, because negative side effects were ob-
served in the context of placebo therapies (Enck et al., 2008). Placebo groups of 
randomized studies reported side effects, which were according to the known side 
effects of the drug (Colagiuri et al., 2012; Rief et al., 2009) and which may as a 
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consequence lead to high drop out rates (Mitsikostas et al., 2011). These symp-
tom developments do not only occur after the intake of inert substances paired 
with negative expectations, or within simulated medical interventions, but as with 
the placebo effect, also in the context of any treatment when subjects or patients 
expect to experience adverse reactions (Bingel et al., 2011). This in turn can have 
serious effects, as treatment improvements may be abolished and adverse symp-
toms can develop, interfering with drug and treatment effects (Enck et al., 2008). 
For this reason, in contrast to the meaning of placebo (“I shall please”), the defini-
tion of the nocebo as meaning “I shall harm” was developed (Hahn, 1997). In 
comparison to the placebo effect, the nocebo effect has been investigated to a 
much lower degree. Although, lately the nocebo effect gained more scientific at-
tention and its influence within the clinical context is increasingly considered. 
1.3 Mechanisms mediating the placebo and nocebo effect 
Today, the mechanisms and effects of the placebo and nocebo phenomenon have 
been increasingly investigated but many questions still prevail. However, research 
over the last years revealed that two mechanisms steer the placebo and nocebo 
response: Associative learning processes such as Pavlovian or behavioral condi-
tioning and expectation (Enck et al., 2008). Depending on the physiological re-
sponse system, one or both of these mechanisms have been shown to steer the 
placebo response. Behavioral conditioning of placebo effects has been demon-
strated for the immune and neuroendocrine system (reviewed in Wendt et al., 
2014), which were modulated only through behavioral conditioning (Benedetti et 
al., 2003; Goebel et al., 2002) and not by induced expectations (Albring et al., 
2012; Benedetti et al., 2003). Both associative learning and expectation mecha-
nisms have been shown to steer placebo effects within numerous physiological 
systems, such as the respiratory, cardiovascular and gastrointestinal system, as 
well as diseases, amongst others depression, multiple sclerosis and Parkinson’s 
disease (reviewed in Enck et al., 2013). Their affects on the nocebo response 
have only been identified in the context of pain and experienced side effects. This 
is due to the ethical agreement of nonmaleficence considering the infliction of pain, 
anxiety and stressful experiences on individuals during clinical or experimental 
study setup in order to gain more insight about its psychological and physical ef-
fects. 
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1.3.1 Associative learning processes steering the nocebo effect 
Associative learning processes such as Pavlovian or behavioral conditioning have 
given the most insight into the origin of placebo and nocebo effects. In general, 
stimuli that have been associated with an adverse reaction or symptom develop-
ment in the past are able to induce unwanted adverse reactions upon re-exposure 
(Figure 2). This has been documented with anticipated nausea in cancer patients 
during chemotherapy (Bovbjerg et al., 1992). Cytotoxic chemotherapy agents (US) 
commonly cause adverse side effects such as nausea and vomiting. During drug 
infusion, neutral stimuli such as the hospital atmosphere, clinical personnel or dis-
tinct odors are present which can, when encountered alone in the future, elicit 
vomiting and nausea (CR) (Bovbjerg et al., 1992). Visual cues alone can recall this 
learning process as allergy patients who were presented a picture of a hayfield 
showed allergic symptoms (reviewed in Ader and Cohen, 1993) and the presenta-
tion of a sealed glass vessel filled with dust caused an asthmatic attack within 
asthma patients (Dekker and Groen, 1956).  
However, the mechanisms of associative learning and expectation cannot be 
viewed dichotomously, as they are interrelated and influence each other. Through 
prior experience, an individual can learn to associate the procedure of taking med-
ication with the development of side effects, which can be viewed as behavioral 
conditioning, but this also influences the expectation of experiencing symptoms in 
future drug intakes. Furthermore, expectations induced through verbal suggestions 
can also function as a CS as they may restore earlier acquired stimuli associa-
tions. 
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Fig. 2: Associative learning processes and their influence on the nocebo response 
An associative learning process, such as classical conditioning, is an important mechanism steering the noce-
bo response. Previous encounters with a drug or treatment (US), which induce adverse responses (UR), such 
as an increase of side effects or symptom development are accompanied with neutral visual or olfactory 
stimuli (NS). Later on when a placebo or sham treatment occurs in the presence of the same formerly neutral 
visual and olfactory stimuli (CS), these may induce similar adverse effects (CR). US= unconditioned stimulus, 
NS= neutral stimulus, UR= unconditioned response, CS= conditioned stimulus, CR= conditioned response 
1.3.2 Expectation processes steering the nocebo effect 
The expectation of either symptom improvement (placebo) or experienced side 
effects or pain (nocebo), play an essential role when patients or study participants 
receive a treatment. Interestingly, as outlined in section 1.4, these expectations of 
experiencing side effects or pain activate similar brain areas as the actual experi-
ence of side effects or pain themselves, which may in turn intensify these percep-
tions (Bingel et al., 2011; Koyama et al., 2005). 
Expectations are typically induced through verbal suggestions and social observa-
tional learning. Verbal suggestions of harm within experimental pain studies, over-
ruled the effects of previous conditioning with a pain reliever (Benedetti et al., 
2003) and abolished the effect of a potent opioid (Bingel et al., 2011). In another 
experiment, subjects were told about the side effects of the immunosuppressive 
drug CsA, which they expected to take. They reported the experience of four typi-
cal side effects of CsA, although they received placebos throughout the entire 
study (Wendt et al., forthcoming). 
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Within the medical treatment context, verbal suggestions have been shown to in-
duce pain and anxiety. The experienced pain during local anesthetic injections 
was higher in patients who were told to expect a slight discomfort (nocebo infor-
mation) than in those who were told to expect to feel comfortable throughout the 
procedure (placebo information) (Varelmann et al., 2010). A further example is a 
group of patients, who were warned about undesirable experiences of noxious 
stimuli during interventional radiological procedures and reported higher levels of 
pain and anxiety than those without negative information (Lang et al., 2005).  
Observational learning of other individuals, who show adverse symptoms after a 
placebo treatment, can increase pain sensitivity and induce symptom development 
as well as the experience of side effects within the observer (Mazzoni et al., 2010; 
Vögtle et al., 2013). This may also induce associative learning mechanisms, as the 
observation of negative events experienced by the demonstrator could operate as 
an US. In addition, further aspects influence the nocebo effect through implicit and 
explicit mechanisms, which can induce associative learning and expectations 
(Figure 3). 
1.3.3 Further factors steering the mechanisms of the nocebo effect 
The mechanisms of the nocebo response, associative learning and expectations, 
are further influenced through factors such as information sources, the doctor-
patient relationship, the personal medical history as well as psychological and bio-
logical factors. 
Information sources can induce strong nocebo effects through negatively worded 
informed consents and patient information leaflets (Wendt et al., forthcoming) 
while increased information given about potential side effects can lead to their 
subsequent rise (Wise et al., 2009). Media information about the amount of side 
effects induced through antidepressants has influenced nocebo responses within 
placebo groups taking two different antidepressants. The placebo group of the tri-
cyclic antidepressant (TCA) trial reported more side effects than the placebo group 
of the selective serotonin reuptake inhibitors (SSRIs) trial. SSRIs were introduced 
in the late 1980s and are known to cause fewer side effects than TCAs (Rief et al., 
2009). Today, it has been speculated that the increase in lactose intolerance 
Introduction - 16 - 
(Vernia et al., 2010) and in side effects of oral contraceptives (Grimes and Schulz, 
2011) may be due to negative information sources. 
Moreover, a negative doctor-patient relationship influences the occurrence and 
strength of the nocebo response (Colloca and Finniss, 2012) and the personal 
medical history can also influence present treatment outcomes. The development 
of symptoms after treatments in the past are strong predictors for developing ad-
verse symptoms in the present (Petrie et al., 2005) and within the treatment con-
text, visual and olfactory cues of a former treatment may induce nocebo responses 
upon re-exposure (Bovbjerg et al., 1992). Lastly, biological and psychological vari-
ables have shown to influence nocebo responses. Females have reported signifi-
cantly more nocebo effects within various experiments (Lorber et al., 2007; Ströh-
le, 2000). However, these effects may be partly due to the fact that males report 
less pain to female experimenters (Flaten et al., 2006). Psychological factors such 
as anticipatory anxiety (Elsenbruch et al., 2012), beliefs about medicines (Nestori-
uc et al., 2010) and somatosensory amplification (Davis et al., 1995) have been 
associated with nocebo responses as well (Figure 3).  
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Fig. 3: Mechanisms of the nocebo response and their adverse effects 
The nocebo effect is based on two different mechanisms. It can be induced through associative learning pro-
cesses, such as classical conditioning and expectation, which can be induced through verbal suggestions or 
observational learning. Current research shows that these mechanisms can induce neurobiological and bio-
chemical changes, which in turn may cause the development of side effects, reduction of drug efficacy, pain 
increase and worsening of symptoms. Further factors have been shown to steer and modulate associative 
learning processes and expectation, such as the personal medical history, the doctor-patient relationship, 
information sources, psychological and biological factors, as well as the general treatment context. 
In conclusion, the mechanisms of nocebo and placebo responses have been 
shown to influence various treatment outcomes, in both negative and beneficial 
ways. These mechanisms need to be investigated in more detail. Insights into their 
effects have been provided by neuroimaging and pharmacological investigations, 
where they have been shown to produce neurobiological changes, which in turn 
interact with biochemical signaling paths of pharmacological drugs.  
1.4 Neurobiological and biochemical actions of the placebo and nocebo 
effect 
Current research revealed that placebo and nocebo effects cannot be explained 
by a single model utilizing neurobiological or biochemical processes. Depending 
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on the physical system studied or the experimental setup, different mechanisms 
take effect. In opposition to the placebo effect, which occurs in a positive psycho-
social environment, the nocebo phenomenon is mainly investigated during pain 
experiments and therefore embedded in a negative context. As a consequence, 
the acquired neurobiological and biochemical measurements reflect those nega-
tive effects on the physical and psychological state of an individual. 
1.4.1 Neurobiological actions of the placebo and nocebo effect 
Neuroimaging methods have provided fascinating insights of neurobiological pro-
cesses during the investigation of expectancy induced nocebo effects (Bingel et 
al., 2011; Kong et al., 2008; Koyama et al., 2005). The nocebo effect seems to be 
based on a cognitive and affective pain path, as a magnetic resonance tomogra-
phy (MRT) study revealed activity within neurobiological structures involved in the-
se pathways during a nocebo response (Kong et al., 2008).  
Opposing effects of placebo and nocebo responses and their neurobiological cor-
relates have been demonstrated in an elegant study in which the opioid analgesic 
remifentanil was administered (Bingel et al., 2011). Participants received painful 
thermal stimuli, which they had to rate on a pain intensity scale from 0 to 100. 
Subsequently, remifentanil was administered intravenously without the subjects’ 
knowledge (hidden application) and the pain intensity decreased from an average 
of 65 to 55. However, when they were informed about the pain reducing properties 
of remifentanil, pain sensation decreased to 39, although the intravenous concen-
tration remained unchanged. In contrast, when the nocebo information was given 
that no more analgesic would be given and the sensation could get worse, pain 
ratings rose to 64, corresponding to the initial value, where no opiods were given. 
Here, the anticipatory anxiety of experiencing pain overruled the effects of the opi-
oid analgesic. Functional magnetic resonance imaging (fMRI) revealed that during 
placebo and nocebo conditions endogenous pain modulatory control systems 
were engaged, but in antagonistic ways. When subjects expected an analgesic 
effect during the placebo condition, the dorsolateral prefrontal cortex, the rostral 
anterior cinculate cortex and the periaquedutal grey were active, which are in-
volved in inhibiting pain and which enhanced the effects of the drug. Whereas dur-
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ing the nocebo condition, increased activity was measured in the hippocampus 
(Bingel et al., 2011). 
Further opposing effects have been shown in an fMRI study where the expectancy 
of increased pain (nocebo) was associated with increased activity in the insular 
cortex (Ic), prefrontal cortex, anterior cingulate cortex (ACC), thalamus and further 
brain areas. Whereas, when the expectation of decreased pain was induced, the 
activity of pain-related brain areas (e.g. ACC, amygdala (Am) and primary soma-
tosensory cortex) was reduced along with the subjective perception of pain (Ko-
yama et al., 2005). In summary, negative expectations may not only shape neural 
processes of painful stimuli, but may also enhance and alter the unpleasantness of 
painful stimuli on a psychophysical level.  
1.4.2 Biochemical actions of the placebo and nocebo effect 
Changes of brain activity during the nocebo effect are associated with neurochem-
ical alterations and pharmacological investigations have increased the understand-
ing of biochemical actions of the nocebo effect (Benedetti et al., 2006). Here, simi-
lar to neuroimaging pain studies, negative and positive expectations are induced 
within study participants regarding the intensity of pain experience. During the ad-
ministration of saline solution (placebo), the activation of the endogenous opioid 
and dopaminergic neurotransmitter systems were measured through positron 
emission tomography (PET). The placebo effect induced an analgesic effect along 
with the activity of opioid neurotransmission in the ACC, Am, nucleus accumbens, 
Ic, oribitofrontal cortex and periaqueductal grey matter. The nocebo response 
caused a hyperalgesic effect and was associated with a deactivation of opioid re-
lease. In addition, the placebo response was reflected in dopaminergic activity in 
the ventral basal ganglia and the nucleus accumbens, whereas the nocebo re-
sponse decreased the dopaminergic activity in those areas (Benedetti et al., 
2006). Therefore, nocebo and placebo responses seem to induce opposing effects 
in brain circuits associated with reward and motivational behavior.  
Further evidence for these opposing effects has been demonstrated in a model 
investigating the antagonistic action of cholecystokinin (CCK) on opiodergic sys-
tems (Benedetti et al., 2007). The hormone CCK is involved in the development of 
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anxiety and panic and appearing to play a modulating role during pain within 
nocebo and placebo responses. A verbally induced expectation of declining pain 
(placebo) resulted in decreased pain and mobilized the endogenous µ-opioid neu-
rotransmission, but this process can be blocked by CCK. Its antagonist proglumide 
binds to CCK-A and CCK-B receptors, which has been shown to inhibit a hyperal-
gesic nocebo effect and an enhancement of the placebo effect (Benedetti et al., 
2007).  
Furthermore, anxiety seems to play an important part during the nocebo effect 
(Benedetti et al., 2006). This has been shown in an experiment, where the intake 
of a placebo pill was combined with the induction of experiencing pain hyperalge-
sia. Participants reported an intensification of pain, paralleled by increased blood 
concentrations of the hormones adrenocorticotropin and cortisol, indicating a 
stress-induced activation of the HPA-axis. Further test groups additionally received 
either the benzodiazepine diazepam, which reduces tension and anxiety; or 
proglumide before the experimental procedure. The hyperalgesic nocebo effect 
was reduced through both diazepam and proglumide with the difference being that 
diazepam also reduced the stress-induced activation of the HPA-axis. Proglumide 
did not seem to reduce anxiety, as the increased release of stress hormones was 
not blocked. In summary, there seem to be two different biochemical means of 
transmission during the nocebo response; the pain enhancing effect of CCK and 
the activation of the HPA-axis respectively (Figure 4).  
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Fig. 4: Biochemical actions of the nocebo response 
The expectation of receiving a painful stimulus (nocebo) leads to anticipatory anxiety, which activates two 
different biochemical means of transmission: the pain enhancing effect of the CCK-ergic pronociceptive sys-
tem and the stress-induced activation of the HPA-axis. Only the pronociceptive system is modulated through 
CCK-antagonists such as proglumide, where the hyperalgesic effects of the nocebo response is blocked, 
while the increased release of stress hormones through activation of the HPA-axis is not affected. The intake 
of benzodiazepines however, causes a reduction of anxiety and blocks both biochemical paths. Note: Anatom-
ical accuracy was subjected in order to illustrate the biochemical actions of the nocebo response. Adapted 
from (Enck et al., 2008). 
In conclusion, neurobiological and biochemical actions behind nocebo responses 
are still poorly understood to this date. Current pharmacological studies however, 
show that the induction of a placebo and nocebo response leads to a complex in-
volvement of various neurotransmitters such as CCK, opioids and dopamine. Fur-
thermore, the same neurobiological and biochemical systems seem to mediate 
both placebo and nocebo responses.  
1.5 The search for predictors of nocebo responses  
Nocebo-induced side effects can result in nonadherence behavior and medication 
discontinuation, unnecessary additional physician visits and added drug intake to 
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counteract occurring side effects. Moreover, as they form confounds within the 
evaluation of clinical drug trials, they may contribute to an overestimation of side 
effects. Consequently, this leads to wasted drug intake and higher health care 
costs. The identification of predictors of nocebo responses can be utilized to im-
prove the efficacy of drug effects as well as the overall physical constitution of pa-
tients. Several studies have identified psychological variables that increase and 
induce nocebo responses. Up to this date, there are no data available indicating 
whether or not and to what extent biological factors, such as gene polymorphisms 
contribute to the nocebo response. Although a few studies have reported stronger 
nocebo effects within females (Lorber et al., 2007; Ströhle, 2000), these effects 
may be partly due to the fact that males report less adverse effects to female ex-
perimenters (Flaten et al., 2006). Therefore, within this thesis, the psychological 
variables, somatosensory amplification and beliefs about medicines, as well as the 
gene polymorphism, catechol-O-methyltransferase (COMT) were tested consider-
ing them to be possible nocebo predictor variables.  
1.5.1 Somatosensory amplification and beliefs about medicines 
Various psychological factors predicting nocebo responses have been identified, 
such as anticipatory anxiety for the experience of visceral pain (Elsenbruch et al., 
2012), worries about experiencing symptoms (Petrie et al., 2005), the trait pessi-
mism for inducing unpleasant feelings after pill intake (Geers et al., 2005), neuroti-
cism (Davis et al., 1995) and a higher somatosensory awareness and amplification 
(Barsky et al., 1999; Davis et al., 1995).  
Somatosensory amplification is a disposition to identify naturally occurring somatic 
and visceral sensations as being very strong, unpleasant and harmful and has re-
cently been associated with hypochondria (Barsky et al., 1990). Patients and study 
participants with increased sensitivity of bodily processes, reported more symp-
toms after placebo intake (Barsky et al., 1999); and healthy subjects with higher 
scores on the somatosensory amplification acale (SSAS), measuring somatosen-
sory amplification, experienced more side effects when taking an antidepressant 
or a placebo (Davis et al., 1995). This may be due to the fact that many individuals 
who experience symptoms, examine their bodies mentally to detect physical 
symptom changes (Rief and Broadbent, 2007). As shown in section 1.4, expecta-
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tions of developing symptoms induce similar neurobiological and biochemical 
pathways, as pharmacological drugs or pain stimuli do. This in turn may promote 
the perception of symptoms, and contributes to nocebo responses. Individuals with 
a medical history of somatic symptoms, have shown more likely to experience a 
nocebo response in the future (Papakostas et al., 2004). Therefore, individuals 
with higher scores in the assessment of somatosensory amplification seem to be 
more likely to experience more side effects.  
Furthermore, nocebo effects may develop because of previous negative experi-
ences with drugs and medical treatments, resulting in classical conditioning pro-
cesses, where individuals associate side effects with such regimens (Figure 2) and 
shape negative expectations regarding side effect development. Acquired beliefs 
about medicines seem to play a pivotal role within nocebo effects and treatment 
efficacy, as negative beliefs about medicines have predicted increased side effect 
reporting during treatment with arthritis medication (Nestoriuc et al., 2010); and 
numerous studies have associated more negative beliefs of medicines with lower 
medical treatment adherence (reviewed in Nestoriuc et al., 2010). 
1.5.2 Gene polymorphisms 
Biological and/or genetic variables predicting nocebo responses are lacking, 
whereas clinical and experimental data on biological and genetic variables predict-
ing placebo responses are rare; however, plasma noradrenaline concentration 
(Ober et al., 2012) and more recently, gene polymorphisms (Furmark et al., 2008; 
Hall et al., 2012; Leuchter et al., 2009; Peciña et al., 2014) have been identified. 
The major degrading enzyme of endocannabinoids FAAH has been found to in-
duce higher placebo analgesia for the FAAH Pro129/Pro129 homozygote (Peciña 
et al., 2014) and within major depressive disorder, the placebo response was 
linked to gene polymorphisms, which modulate monoaminergic tone (Leuchter et 
al., 2009). A serotonin-related gene polymorphism has been linked to placebo-
induced anxiety relief (Furmark et al., 2008) and genetic polymorphisms in the 
COMT gene (Val158Met) predicted placebo responses in patients with irritable 
bowel syndrome (Hall et al., 2012).  
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The neurological pathway of the placebo response has been intensively investi-
gated and points to the involvement of a dopamine-reward circuitry (Pacheco-
López et al., 2006). The enzyme catechol-O-methyltransferase (COMT), degrades 
dopamine and plays a critical role in the regulation of prefrontal and mid-brain do-
pamine signaling (Yavich et al., 2007); its coding gene occurs in allelic variants. 
The COMT Val158Met polymorphism has been investigated most extensively and 
has been linked to memory function, cognition, as well as emotional and pain pro-
cessing (reviewed in Hall et al., 2012). In this particular functional single-nucleotide 
polymorphism in the COMT gene, is a base G to base A transition, which leads to 
a valine to methionine substitution at position 158 (Val158Met) rs4680 (Lotta et al., 
1995). The valine form catabolizes dopamine three to four-times more than the 
methionine form (Lachman et al., 1996). The less efficient catabolization in 
Met/Met homozygote carriers leads to a higher amount of dopamine in the brain 
compared to Val/Val homozygote carriers and individuals with the Val/Met variant. 
This seems to influence the perception of well-being, as individuals with the Met 
variant have been shown to have a higher ability to experience reward compared 
to Val/Val homozygous carriers (Lancaster et al., 2012). Complementing these 
results, Met/Met homozygous carriers showed the strongest placebo response in a 
recent study, especially when examined by a caring practitioner, compared to indi-
viduals of the other genotypes (Hall et al., 2012). 
In the experiment of this thesis, the nocebo effect was investigated after the intake 
of the drug CsA and placebo administration. Animal studies, utilizing CsA as an 
US, have shown that conditioned immunosuppressive effects are regulated by the 
sympathetic nervous system with noradrenaline being the main transmitter (Exton 
et al., 2002). Noradrenaline and adrenaline are regulated by the enzyme COMT 
(Molinoff and Axelrod, 1971) and plasma noradrenaline levels have been shown to 
predict the individual placebo response in humans within behavioral conditioned 
immunosuppressive effects with CsA (Ober et al., 2012). It seems therefore likely 
to find potential biomarkers of nocebo responses within the COMT Val158Met poly-
morphism. 
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1.6 Thesis objectives and hypotheses 
The aim of the present study was to identify possible psychological and biological 
predictors of nocebo responses after drug and placebo intake. Nocebo-induced 
side effects are not only of relevance for clinical trials, but also play a major role in 
drug discontinuation in clinical practice, thereby negatively affecting treatment effi-
cacy as well as patient adherence and compliance (Enck et al., 2013; Rief et al., 
2011). Since experimental and clinical data document a large interindividual varia-
bility in nocebo responses, one of the major challenges in this research area is to 
identify such predictors (Barsky et al., 1999; Davis et al., 1995; Elsenbruch et al., 
2012; Geers et al., 2005) in order to minimize nocebo effects and increase medical 
treatment benefits for patients. 
A number of psychological predictors of the nocebo response have been identi-
fied, such as anxiety, beliefs about medicines and somatosensory amplification 
(see section 1.5.1). However, to this date, there are no biological predictors for the 
nocebo response, although recently, polymorphisms in the COMT gene 
(Val158Met) have been linked to placebo responses. As a result, this research pro-
ject investigated whether the trait somatosensory amplification, beliefs about med-
icines and the COMT functional Val158Met polymorphism could be also possible 
predictors of nocebo effects. 
In order to assess nocebo responses after medication and placebo intake, a study 
program on learned immunosuppressive placebo responses (Albring et al., 2014) 
with 62 healthy male subjects, was employed. The unique advantage of this condi-
tioning model is the ability to analyze intra-individual nocebo responses, measured 
through CsA-specific and general side effects, after the intake of CsA during the 
acquisition phase as well as after placebo intake during the evocation phase. Psy-
chological, immunological, cardiovascular and neuroendocrine parameters were 
analyzed before and after medication or placebo intake in order to test their influ-
ence on specific and general side effect development. Drug specific and general 
side effects were assessed throughout the whole study and analyzed to determine 
if they were associated with somatosensory amplification, beliefs about medicines 
and the COMT functional Val158Met polymorphism; therefore being possible noce-
bo predictors. 
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2 Materials and Methods 
2.1 Study participants 
This study consisted of 62 healthy males of Caucasian descent (age range: 18-40 
years, mean age: 25.5 ± 0.5 years), recruited through public advertisement in the 
surrounding community. Before the first study day, all participants received a writ-
ten form as well as a personal briefing about the details of the experimental setup 
and possible risks of cyclosporine A (CsA) intake. However, they received no in-
formation about the study hypothesis or the conditioning paradigm. Participants 
gave written informed consent and were informed that they were able to discontin-
ue participation at any point in time. The study was approved by the local ethics 
committee for human investigations of the University Hospital Essen, and partici-
pants received 500 Euros as compensation; they were also insured through the 
University Hospital Essen. 
Subsequently, subjects underwent an extensive physical and psychological as-
sessment (self-reported questionnaires, general anamnesis and medical history). 
An electrocardiogram and ultrasonography of the kidneys were performed and 
evaluated by the physicians of the Department of Nephrology. Subjects were ex-
cluded if one of the following criteria was identified: daily intake of medication, 
blood donations >200 ml within the last two months, intolerance for substances 
(e.g. lactose) used in the study, previous participation in pharmacological studies 
or other medical exclusion criteria (e.g. disorders of immune or neuroendocrine 
system, previous or persistent psychiatric disorders, addiction, allergies, signs of 
cardiovascular, hematologic or nephrologic disorders, respiratory problems or dia-
betes mellitus). 
2.2 Cyclosporine A 
In this thesis, the drug CsA was utilized for assessing the nocebo effect, in the 
form of reported side effects after medication and placebo intake. CsA is a potent 
immunosuppressant widely used in organ transplantation to prevent rejection, as 
well as in cases of psoriasis, atopic dermatitis and occasionally in rheumatoid ar-
thritis (Kapturczak et al., 2004). CsA inhibits the activity of the Ca2+/calmodulin-
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dependent-activated serine / threonine phosphatase calcineurin (CaN), which op-
erates as a phosphatase, amongst other cells, within immunocompetent T-cells, 
where it promotes the transcription of interleukin (IL)-2, interferon (IFN)-γ and re-
lated genes through dephosphorylating the transcription factor nuclear factor of 
activated T-cells (NF-AT). When Ca2+ enters the cell, the displacement of an auto-
inhibitory domain by the Ca2+-calmodulin complex activates the catalytic subunit of 
CaN (Steinbach et al., 2007). A DNA-binding complex is formed through hypo-
phosphorylated NF-AT entering the nucleus, which leads to enhanced IL-2 and 
IFN-γ production.  
Therefore, CaN modulates a key transcription factor involved in immune feedback 
and is therewith directly responsible for the activation of T cells. CsA is a calcineu-
rin inhibitor, which employs its cellular effects by binding to a family of proteins 
called immunophilins and targets CaN. The immunophilin cyclophilin A predomi-
nantly binds CsA, which in turn enhances the immunophilin’s affinity to CaN. (re-
viewed in Kapturczak et al., 2004). An inhibitory complex with CaN is subsequently 
formed, leading to the inhibition of CaN activity. Conclusively, CsA prevents the 
dephosphorylation of NF-AT through calcineurin and as a result its immunosup-
pressive effect is manifested through the inhibition of the IL-2 and IFN-γ production 
(Batiuk and Halloran, 1997) (Figure 5). 
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Fig. 5: The calcineurin signaling pathway and the action mechanism of CsA 
An increase of intracellular Ca2+ activates the development of a Ca2+–calmodulin complex. This in turn, acti-
vates the enzyme calcineurin (CaN), which acts as a serine/ threonine phosphatase. Subsequently it 
dephosphorylates the transcription factor NF-AT (nuclear factor of activated T-cells), which then passes 
through into the nucleus, where it initiates the transcription of NF-AT regulated genes. CsA inhibits the enzy-
matic activity of CaN and consequently inhibits the expression of NF-AT regulated genes. Modified from 
(Steinbach et al., 2007). 
During the treatment with CsA, unwanted side effects such as paresthesia, ne-
phrotoxicity, high blood pressure, hirsutism and a higher vulnerability towards in-
fections and malignant tumors may occur (Mihatsch et al., 1989); however, sub-
jects of this study only took four dosages of CsA during three days. For this rea-
son, only mild side effects could have occurred, such as heat sensation in the 
hands and head, nausea and discomfort in the intestine and stomach, fatigue and 
a tingling sensation in the hands. 
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2.3 Study design 
2.3.1 The behavioral conditioning paradigm 
In a well-established design of a study program on behavioral conditioning of im-
mune functions (Albring et al., 2014), subjects were randomly allocated to three 
different double-blind placebo-controlled groups, in order to identify possible bio-
logical and psychological predictors of nocebo responses after treatment with the 
immunosuppressive drug CsA. Within this program, CsA (unconditioned stimu-
lus/US) was paired with a gustatory stimulus (conditioned stimulus/CS) during ac-
quisition. Mere re-exposition to the CS during evocation is mimicking the im-
munopharmacological properties of CsA, reflected by impaired Th1 cytokine pro-
duction and decreased T cell proliferation (Goebel et al., 2002; Wirth et al., 2011). 
The unique advantage of the design described here, is the ability to analyze intra-
individual nocebo responses, after intake of CsA during the acquisition phase as 
well as after placebo intake during the evocation phase. 
On experimental days 1 (6 pm), 2 (8 am and 6 pm) and 3 (8 am) during the first 
week of medication intake, all subjects received four oral doses of 2.5mg/kg body 
weight of the immunosuppressive drug CsA (Sandimmun optoral®, Novartis) in 
capsule form. This quantity was chosen based on previous studies successfully 
utilizing this dosage (Albring et al., 2014; Goebel et al., 2002; Wirth et al., 2011). 
The CsA capsules were manufactured by the pharmacy of the University Hospital 
Essen to be indistinguishable from the placebo capsules in taste and smell. To 
achieve this, the CsA capsules were coated with a white film of gelatine and the 
interstitial were filled with lactose powder. The first (Csa_placebo_drink, n=24) and 
second (Csa_10%CsA_drink, n=26) groups received a green-colored novel-tasting 
drink (150 ml strawberry milk aromatized with lavender oil; CS) with each capsule 
intake during the whole study, which has been previously established and utilized 
(Albring et al., 2014; Goebel et al., 2002; Wirth et al., 2011) (Figure 6).  
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Fig. 6: The conditioned and unconditioned stimuli. 
The conditioned stimulus is made out of a green-colored novel-tasting drink (150 ml strawberry milk aroma-
tized with lavender oil) and taken together with the unconditioned stimulus; the immunosuppressive drug CsA 
(Sandimmun optoral®, Novartis) in capsule form. 
A pause of five days followed to allow drug wash out. During the following eight 
days, subjects of group 1 (Csa_placebo_drink) received identical looking capsules 
containing a placebo (lactose powder), whereas subjects of group 2 
(Csa_10%CsA_drink, n=26) and group 3 (Csa_10%CsA, n=12) took a subthera-
peutic dose of CsA (0.25 mg/kg) fourteen times; twice a day (8 am and 6 pm re-
spectively) (Figure 7). In order to increase the sample size of this study, all three 
groups were included, although only group 1 received placebo capsules during the 
“Placebo” phase and only groups 1 and 2 received the CS during the whole study. 
However, these different treatments had no effect on the investigated parameters 
of interest of this thesis. Since CsA can cause noticeable side effects, immunolog-
ical, cardiovascular and neuroendocrine parameters were closely monitored during 
Medication and “Placebo” intake (Figure 7; Pre I - Post II). 
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Fig. 7: Experimental design 
On experimental days 1 (6 pm), 2 (8 am and 6 pm) and 3 (8 am) during medication intake, all subjects in each 
of the three treatment groups received four oral doses of 2.5mg/kg body weight of the immunosuppressive 
drug CsA (Sandimmun optoral®, Novartis) in capsule form. In addition, subjects in groups 1 (n=24) and 2 
(n=26) received the CS (drink) with each capsule (CsA) intake, whereas subjects in group 3 (n=12) were not 
exposed to the CS (A). After five days wash out time, subjects either received identical looking capsules con-
taining a placebo (lactose powder) or a subtherapeutic dose of CsA (0.25 mg/kg) fourteen times, twice a day 
(8 am and 6 pm respectively) with (groups 1 and 2) or without (group 3) the CS (B). To analyze possible 
nocebo effects, twelve hours after each capsule intake, participants were asked to report the amount and 
intensity of any drug (CsA) specific side effect. Before the start of the study, before (Pre II) as well as after 
“Placebo” (Post II) intake, the GASE (Generic Assessment of Side Effects) questionnaire was additionally 
filled out to analyze general treatment side effects. Blood was drawn on the first day for baseline measure-
ment (Pre I), on day 3 (Post I) to analyze the pharmacological effect of CsA, on day 8 (Pre II) and 15 (Post II) 
to determine both possible residual effects of the drug and effects on physiological parameters after treatment 
with “Placebo” (subtherapeutical doses of CsA). 
2.3.2 CsA dose response: definition of the subtherapeutic dose  
The utilized subtherapeutic dose of 0.25 mg/kg CsA, was determined in a previous 
pilot study (Albring et al., 2014). Participants received pills containing 0.25 mg/kg 
CsA (10% of the dose used as an US) four times during three consecutive days 
delivered at the same time points as during the acquisition phase of the condition-
ing process. Blood was drawn each time before and after CsA intake and analyzed 
for CsA levels as well as functional immune parameters. A subtherapeutic dose of 
CsA was barely detectable in whole blood and did not significantly affect IL-2 se-
cretion of anti-CD3 stimulated peripheral blood mononuclear cells (PBMCs). 
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2.4 Behavioral parameters 
2.4.1 Measurement of side effects 
Before the start of the study, subjects completed the Generic Assessment of Side 
Effects questionnaire (GASE) (Rief et al., 2011), assessing psychological and 
medical indispositions of the last seven days (Figure 7A; Pre I). The GASE in-
quires the most frequent side effects in clinical trials according to FDA statistics 
and it also allows the assessment of the attribution of symptoms to a specific drug. 
Before the first intake of placebo capsules, the GASE was completed again, as-
sessing those side effects that occurred during the medication intake (Figure 7A; 
Pre II). In addition, subjects filled out the GASE after fourteen intakes of capsules 
containing either no pharmacological agents (placebo) or a subtherapeutic dose of 
CsA (0.25 mg/kg) respectively, in order to analyze possible unwanted side effects, 
which were ascribed to the “Placebo” treatment (Figure 7B; Post II). During those 
two measurement points, only symptoms that were attributed to the alleged drug 
were counted. Additionally, subjects were asked at each visit during Medication 
and “Placebo” intake, to rate CsA-specific side effects on a five-point Lickert scale 
(heat sensation in the hands and head, nausea and discomfort in the intestine and 
stomach, fatigue, tingling sensation in the hands, (0/”not at all’’; 4/’’very intense’’) 
(Figure 7). To measure the expectation of experiencing side effects during study 
participation, subjects were asked before the first pill intake how high they would 
estimate the chance of experiencing adverse effects on a percentage scale from 0 
to 100 (Fig. 7A; Pre I). 
2.4.2 Psychological trait variables 
Questionnaires assessing psychological trait variables were filled out before the 
first study day (Figure 7A; Pre I). A general anamnesis; traits such as optimism 
and pessimism (revised Life Orientation Test /LOT-R) (Herzberg et al., 2006); so-
matosensory amplification (somatosensory amplification scale/SSAS) measuring a 
disposition to identify naturally occurring somatic and visceral sensations as being 
very strong, unpleasant and harmful (Barsky et al., 1990); beliefs about medicines 
(beliefs about medicines questionnaire_extended version/BMQ)(Horne et al., 
1999), assessing patients’ expectations and perceptions regarding the effects of 
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medicines, through judging the personal need of drugs relative to concerns about 
their risk factors, such as side effect development. The BMQ is comprised of six 
subscales: “BMQ_general harm,” the belief that medication will do harm in gen-
eral; “BMQ_general overuse,” the perception of how doctors use medicine and 
place too much emphasis in them; “BMQ_general benefit,” the belief that a benefi-
cial treatment can be achieved through medicines; “BMQ_sensitive soma,” the 
sensitivity towards drug effects; “BMQ_specific necessity,” the dependence on 
medication; “BMQ_specific concerns,” being concerned about drug side effects 
and feeling uneasy when taking drugs. In addition, the trait version of the State-
Trait Anxiety Inventory (STAI) (Spielberger et al., 1983), as well as physical activity 
(Freiburger Fragebogen zur körperlichen Aktivität; FFkA) (Frey et al., 1999) were 
analyzed. In order to exclude any participants with high depression scores, the 
Hospital Anxiety and Depression Scale (HADS-D) (Bjelland et al., 2002) was also 
utilized.  
2.5 Measurement of CsA blood concentrations and cardiovascular pa-
rameters  
CsA concentrations in whole blood were assessed by the central laboratory of the 
University Hospital of Essen, using Siemens Dimension Flex reagent cartridge 
(Erlangen, Germany), according to the manufacturer’s instructions. The blood 
pressure was measured before every blood withdrawal using a sphygmomanome-
ter and in addition the heart rate was recorded. 
2.6 Immunological analyses 
2.6.1 Cell isolation 
In order to determine the effects of CsA, PBMCs were isolated by density gradient 
centrifugation (Ficoll-Paque™ Plus, GE Healthcare, Munich, Germany) from hepa-
rinized whole blood. To achieve this, blood was diluted in the ratio of 1:1 with PBS 
(Phosphate Buffered Saline, Life Technologies, Darmstadt, Germany) and subse-
quently layered on Ficoll. Erythrocytes and granulocytes were then centrifugalized 
through the Ficoll due to their higher density, whereas PBMCs and thrombocytes 
sediment between Ficoll and plasma. This layer was carefully collected with a pi-
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pette and in order to remove the thrombocytes, as well as the remains of plasma 
and Ficoll, cells were washed twice with Hanks’ Balanced Salt Solution (HBSS, 
Life Technologies, Darmstadt, Germany). The cell pellet was subsequently resus-
pended in 2ml of cell culture medium (Roswell Park Memorial Institute (RPMI) 
1640 supplemented with GlutaMAX I, 25 mMHepes, 10% fetal bovine serum, 50 
µg/ml gentamicin; Life Technologies, Darmstadt, Germany) and counted with an 
automated hematology analyser (KX-21 N, Sysmex Deutschland GmbH, Norder-
stedt, Germany) and in the last step adjusted to 2.5 × 106 cells/ml in RPMI. 
2.6.2 Determination of IL-2 production 
PBMC suspensions (2.5 × 106 cells/ml) were transferred to 96-well flat bottom tis-
sue culture plates and were stimulated with 20 ng/ml of soluble mouse anti-human 
CD3 monoclonal antibody (clone: HIT3a; BD Pharmingen, San Diego, USA) for 
24h (37°C, 5% CO2). Concentration of IL-2 in culture supernatants was quantified 
using a commercial enzyme linked immunosorbent assay (ELISA) (Biolegend, San 
Diego, USA) according to the manufacturer´s instructions with the usage of Flu-
ostar OPTIMA Microplate Readers (BMG Labtech, Offenbach, Germany). The 
samples were diluted for the subsequent measurement with Assay Diluent in the 
ratio of 1:5. 
2.6.3 IL-2 mRNA expression analysis 
PBMCs (2.5 × 106 cells/ml) were stimulated with 40 ng/ml of soluble mouse anti-
human CD3 monoclonal antibody (clone: HIT3a, BD Pharmingen) for 4 h (37°C, 
5% CO2). Total ribonucleic acid (RNA) was extracted using the RNeasy Micro Kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s recommendations. 
The concentration of RNA was spectrometrically determined in the wavelength of 
260 nm with the BioPhotometer (Eppendorf, Hamburg, Germany). Single-stranded 
complementary deoxyribonucleic acid (cDNA) was synthesized using a High Ca-
pacity cDNA Reverse Transcription Kit (Applied Biosystems, Darmstadt, Germa-
ny). Real-time quantitative polymerase chain reaction (PCR) was performed on a 
7500 Fast Real-Time PCR system (Applied Biosystems, Darmstadt, Germany) 
using Fast qPCRMasterMix Plus Low Rox (Eurogentec, Cologne, Germany) and 
the following cycling conditions: 5 min at 95°C followed by 40 cycles of 3 sec at 
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95°C, 20 sec at 60°C and 26 sec at 72°C. Primers (forward: 5'-
CCAGGATGCTCACATTTAAGTTTTAC-3'; reverse: 5'-
GAGGTTTGAGTTCTTCTTCTAGAC-3' ACTGA) and probes (5'-6-FAM-
TGCCCAAGAAGGCCACAGAACTGAA-BHQ1-3') were purchased from Micro-
synth (Balgach, Switzerland). For quantification of IL-2 mRNA expression, serially 
diluted cDNA samples generated from purified specific PCR products (High Pure 
PCR Product Purification Kit, Roche Diagnostics, Mannheim, Germany) were used 
as external standards in each run. 
2.6.4 Determination of proliferation rate of CD4+ T cells 
The proliferation rate of CD4+ T cells was measured by flow cytometry using the 
Click-iT® EdU cell proliferation assay (Invitrogen, Darmstadt, Germany) according 
to the manufacturer’s instructions. Briefly, PBMCs (1.25 x 106 cells/ml) were stimu-
lated in 96-well round bottom tissue culture plates with 2.5  µg/ml of soluble mouse 
anti-human CD3 monoclonal antibody (clone: HIT3a, BD Pharmingen,) for 72 h 
(37°C, 5% CO2). The thymidine analogue 5-ethynyl-2´-deoxyuridine (EdU), which 
is incorporated during DNA synthesis, was added to the cells at a concentration of 
10 µM for the last 48 h of culture. After incubation, cells were washed and stained 
with APC conjugated anti-human CD4 (clone RPA-T4, BD Pharmingen) antibody. 
Cells were fixed with 4% paraformaldehyde and permeabilized using a sapo-
nin-based permeabilization reagent. Afterwards, cells were incubated with the 
Click-iT® reaction cocktail. The percentage of proliferating CD4+ T cells was ana-
lyzed on a FACS (fluorescence-activated cell sorting) Canto II flow cytometer us-
ing FACS Diva software (BD Immunocytometry Systems, Heidelberg, Germany). 
2.6.5 Determination of CD3+, CD3+CD4+ and CD3+CD8+ cells 
In order to determine CD3+, CD3+CD4+ and CD3+CD8+ cells, PBMC suspensions 
(2.5 × 106 cells/ml) were incubated with the following fluorochrome-conjugated 
monoclonal antibodies: anti-human CD3 (clone SK7, BD Pharmingen, Heidelberg, 
Germany), anti-human CD4 (clone RPA-T4, AbD Serotec, Düsseldorf, Germany) 
and anti-human CD8 (clone SK1, BD Pharmingen, Heidelberg, Germany). Anti-
body labeling was performed by a standard lyse-wash procedure using FACSTM 
lysing solution (BD Pharmingen, Heidelberg, Germany) and supplemented PBS 
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(Dulbecco’s PBS without calcium and magnesium, 2% FBS, 0.1% NaN3). Lym-
phocytes were identified by forward and sideward scatter characteristics. Ten 
thousand lymphocytes from each sample were analyzed on a FACS Canto II flow 
cytometer using FACS Diva 6.01 software (BD Immunocytometry Systems, Hei-
delberg, Germany). T cells were identified by CD3 staining, T helper cells by 
CD3/CD4 double-staining and cytotoxic T cells by CD3/CD8 double-staining. Total 
cell counts were obtained with an automated cell counter (KX-21N, Sysmex 
Deutschland GmbH, Norderstedt, Germany). 
2.7 Neuroendocrine parameters 
2.7.1 Measurement of cortisol concentration in plasma 
Plasma cortisol levels were measured using a commercial enzyme-linked im-
munosorbent assay (Cortisol ELISA, IBL International, Hamburg, Germany) ac-
cording to the test protocol of the manufacturer and were analyzed on a Fluostar 
OPTIMA Microplate Reader (BMG Labtech, Offenbach, Germany). The samples 
were diluted for the subsequent measurement with PBS in the ratio of 1:50. Intra- 
and interassay variances were 5.6% and 6.9%, respectively. The detection limit for 
cortisol was 0.3 ng/ml. 
2.7.2 Measurement of catecholamine concentration in plasma 
Catecholamines were isolated from plasma through selective adsorption on alu-
minium oxide. Noradrenaline and adrenaline concentrations were determined at 
the Department of Nephrology, University Hospital Essen, through high-
performance liquid chromatography (HPLC) with electrochemical detection 
(ChromSystems, Instruments and Chemicals GmbH, Munich, Germany) according 
to the manufacturer’s instructions. 
2.8 Genotyping 
Genomic DNA was extracted from whole blood using peqGOLD Blood DNA Mini 
Kit (Erlangen, Germany) according to the manufacturer’s protocol. DNA concentra-
tion was determined through the Eppendorf BioPhotometer® plus. Genotyping was 
performed on a 7500 Fast Real-Time PCR System using the TaqMan SNP Geno-
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typing assay for rs4680 (C_25746809_50) and the TaqMan genotyping master mix 
(Applied Biosystems, Darmstadt, Germany) following the manufacturer’s instruc-
tions. Each individual DNA sample was amplified in a total volume of 25 µl, con-
sisting of 11.25 µl DNA, containing 10ng of DNA, 12.5 µl master mix and 1.25 µl 
SNP assay. In addition, negative and positive controls were run through the cycle 
and determination was performed with duplicates. Cycling conditions were as fol-
lows: 10 min at 95°C HOLD, 15 sec at 92°C DENATURE, 1 min at 60°C 
ANNEAL/EXTEND. Allelic discrimination analysis was performed with the SDS 
version 1.4 software (Applied Biosystems, Foster City, USA).  
2.9 Statistical analysis 
Neuroendocrine, immunological, cardiovascular parameters, as well as CsA levels 
in whole blood were analyzed using multivariate analysis of variance (ANOVAs). 
Psychological characteristics as well as behavioral parameters were compared 
with univariate analysis of variances (ANOVA) followed by Bonferroni post hoc 
tests. Pearson correlations were additionally, where applicable, measured. Calcu-
lations were performed with PASW statistics version 18 (SPSS, Chicago, IL, USA). 
If not stated otherwise, all p-values are asymptotic, two-sided and corrected for 
multiple testing. The significance-level was set at p<0.05. Results are displayed as 
mean ± standard error of the mean (SEM). 
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3 Results 
3.1 Analysis of the three experimental groups  
Biological and psychological predictors of nocebo responses after short term 
treatment with the immunosuppressive drug CsA were analyzed after three days 
of medication intake, as well as during eight days of receiving either placebo or a 
subtherapeutic dose of CsA (0.25 mg/kg) respectively.  
In the first step, possible differences between treatment groups 1 to 3 in all varia-
bles were analyzed. Subjects in these groups did not differ in any behavioral pa-
rameters, such as sociodemographic and psychological trait variables (Table 1).  
Treatment group Group 1 (n=24) Group 2 (n=26) Group 3 (n=12) 
SSAS 
BMQ_general harm 
BMQ_general overuse 
BMQ_general benefit 
BMQ_sensitive soma 
BMQ_specific necessity 
BMQ_specific concerns 
Age (years) 
Body mass index (kg/m²) 
Physical activity (FFkA) 
Trait anxiety (STAI) 
LOT(R) Pessimism 
LOT(R) Optimism 
24.8 ± 1.1 
9.8 ± 0.6 
13.7 ± 0.5 
15.7 ± 0.5 
7.7 ± 0.6 
7.6 ± 0.4 
9.6 ± 0.7 
25.0 ± 0.7 
22.5 ± 1.1 
42.3 ± 6.8 
33.1 ± 1.3 
4.0 ± 0.5 
9.4 ± 0.5 
25.9 ± 1.1 
9.2 ± 0.7 
12.9 ± 0.6 
16.4 ± 0.5 
8.3 ± 0.7 
7.8 ± 0.5 
9.2 ± 0.9 
25.9 ± 0.9 
22.3 ± 1.4 
37.2 ± 5.3 
37.3 ± 1.8 
4.9 ± 0.5 
9.0 ± 0.4 
27.1 ± 1.4 
10.5 ± 0.7 
13,7 ± 0.7 
15.6 ± 0.7 
9.6 ± 1.0 
8.1 ± 0.8 
11.3 ± 1.1 
25.5 ± 0.9 
24.2 ± 1.0 
51.5 ± 9.3 
36.3 ± 1.8 
4.8 ± 0.7 
8.8 ± 0.5 
Tab. 1: Sociodemographic and psychological characteristics of the three experimental groups 
SSAS, BMQ_general harm, BMQ_general overuse, BMQ_general benefit, BMQ_sensitive soma, 
BMQ_specific necessity and BMQ_specific, age, body mass index, physical activity (FFkA), trait anxiety 
(STAI) scores, LOT(R) pessimism and optimism were compared between all three treatment groups using 
univariate ANOVA. Groups did not significantly differ in any of the variables listed. Data are shown as mean ± 
SEM; all p>0.05 
The analysis of immunological and cardiovascular parameters also revealed no 
differences between treatment groups 1 to 3 during Medication and “Placebo” in-
take (Table 2). In all groups, the CsA concentration in whole blood rose significant-
ly after four intakes, whereas the IL-2 concentration in culture supernatant de-
creased significantly. Post hoc tests revealed significant time effects for the CsA 
levels from Pre I to Post I (Group 1: t=-11.4; p<0.001; Group 2: t=-30.6; p<0.001; 
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Group 3: t=-8.8; p<0.001), as well as significant time effects for the IL-2 protein 
concentrations from Pre I to Post I for all three groups (Group 1: t=5.0; p<0.001; 
Group 2: t=3.9; p<0.001; Group 3: t=6.6; p<0.001) (Table 2). The only difference 
between the three treatment groups was measured after fourteen subtherapeutical 
dose intakes of CsA in groups 2 and 3, where marginal values were measured 
compared to group 1. Post hoc tests revealed significant time effects from Pre II to 
Post II for the groups 2 and 3 (Group 2: t=-6.5; p<0.001; Group 3: t=-8.8; p<0.001); 
however, this treatment difference had no influence on IL-2 production and cardio-
vascular parameters for all groups (Table 2). 
 Group Medication  “Placebo” 
  Pre I Post I  Pre II Post II 
CsA levels in 
whole blood 
(ng/ml) 
IL-2 in culture 
supernatant 
(pg/ml) 
Heart rate 
(beats/min) 
Systolic BP 
(mmHG) 
Diastolic BP 
(mmHG) 
Group 1 
Group 2 
Group 3 
Group 1 
Group 2 
Group 3 
Group 1 
Group 2 
Group 3 
Group 1 
Group 2 
Group 3 
Group 1 
Group 2 
Group 3 
n.d. 
n.d. 
n.d. 
488.4 ± 76.4 
350.5 ± 78.2 
278.4 ± 43.9 
71.9 ± 2.4 
73.4 ± 1.8 
71.3 ± 2.1 
122.8 ± 2.1 
127.5 ± 2.0 
125.4 ± 3.6 
83.5 ± 1.5 
85.0 ± 1.5 
84.6 ± 2.3 
1285.8 ± 41.3 t* 
1096.1 ± 94.0 t* 
1482.3 ± 77.6 t* 
128.3 ± 18.3 t* 
115.7 ± 22.2 t* 
164.4 ± 31.6 t* 
69.1 ± 1.8 
68.1 ± 1.9 
69.7 ± 2.3 
123.1 ± 2.4 
127.1 ± 1.8 
126.9 ± 2.3 
85.1 ± 2.0 
87.7 ± 1.5 
88.3 ± 1.3 
 n.d. 
n.d. 
n.d. 
452.2 ± 68.8 
341.6 ± 60.9 
378.6 ± 60.8 
64.8 ± 1.9 
70.9 ± 2.1 
72.0 ± 3.2 
122.7 ± 1.7 
125.7 ± 2.2 
126.7 ± 3.6 
82.1 ± 1.4 
81.9 ± 1.4 
82.5 ± 1.7 
n.d. 
60.4 ± 5.5 t* 
81.9 ± 6.5 t* 
432.5 ± 75.8 
303.0 ± 54.5 
492.8 ± 83.5 
65.6 ± 2.2 
65.7 ± 2.0 
71.4 ± 5.2 
121.6 ± 2.2 
123.9 ± 1.7 
119.6 ± 3.9 
81.5 ± 1.6 
82.8 ± 1.1 
83.3 ± 1.7 
Tab. 2: CsA levels, IL-2 concentrations and cardiovascular parameters of the three experimental 
groups during Medication and “Placebo” intake 
CsA treatment during Medication significantly increased CsA serum levels in all groups significantly and sup-
pressed IL-2 protein concentrations after anti-CD3 stimulation, however, it did not affect cardiovascular pa-
rameters in all groups. During the “Placebo” condition, treatment with subtherapeutical doses of CsA slightly 
increased CsA levels (groups 2 and 3), however, effected neither IL-2 production nor cardiovascular parame-
ters in these groups. CsA levels, immune and cardiovascular parameters were analyzed with multivariate 
ANOVAs (t= time effect; n.d= not detectable, <25 ng/ml). In case of significant F tests, these were followed by 
Bonferroni post hoc tests. Data are shown as mean ± SEM; *p<0.001 
Subjects of all three groups did not significantly differ in their perceived treatment 
side effects documented with the GASE before study entry (Baseline; F=0.1; n.s.), 
as well as in their general (F=1.0; n.s.) and CsA-specific side effects (F=1.4; n.s.) 
during Medication intake (Figure 7, Post I). Moreover, during “Placebo” treatment, 
no significant group differences were observed either in reported general (GASE; 
Post II (F=0.5; n.s.) or in CsA-specific side effects (F=0.4; n.s.)(Table 3). 
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Tab. 3: CsA-specific and general side effects of the three experimental groups during Medication 
and “Placebo” intake 
Treatment groups did not significantly differ in reported CsA-specific side effects and general side effects 
analyzed with the GASE, either during the Medication or during the “Placebo” condition. All measured side 
effects were compared between all three treatment groups using univariate ANOVA. Data are shown as mean 
± SEM; all p>0.05 
3.2 Genotyping and subsequent analysis  
After confirming that treatment groups showed no significant differences in report-
ed side effects, or psychological and physical parameters, volunteers were then 
put into one group and subsequently compared according to the respective three 
genotype groups: homozygotes for the Val158allele (Val/Val), heterozygotes 
(Val/Met), and homozygotes for the Met158allele (Met/Met). Genotyping revealed 
allele frequencies of 30.7% (Val/Val; n=19), 54.8% (Val/Met; n=34) and 14.5% 
(Met/Met; n=9) for the COMT Val158Met polymorphism. 
3.2.1 General and CsA-specific side effects 
Subsequent analyses revealed significant differences between the three genotype 
groups and their experienced side effects. When analyzing general psychological 
and medical indispositions with the GASE questionnaire before study entry, 
Val/Val homozygote carriers reported significantly more general psychological and 
medical indispositions (7.8 ± 1.8) compared to the Met/Met (1.3 ± 0.7) and Val/Met 
groups (3.9 ± 0.8) (F=4.6; p<0.01). Post hoc analysis showed a significant differ-
ence between Val/Val and Met/Met (p<0.05). Furthermore, Val/Val homozygote 
carriers also reported significantly more general psychological and medical indis-
positions (GASE) after Medication intake (F=5.9; p<0.01). Post hoc analysis 
showed a significant difference between Val/Val and Val/Met; p<0.01, as well as 
between Val/Val and Met/Met; p<0.05 (Figure 8a). Interestingly, also after “Place-
bo” treatment, this group reported more experienced general side effects recur-
rently (F=4.7; p<0.05) (Val/Val vs. Val/Met p<0.05) (Figure 8b).  
Medication  “Placebo” 
Group CsA-specific 
side effects 
General side 
effects (GASE) 
 CsA-specific 
side effects 
General side 
effects (GASE) 
Group 1 
Group 2 
Group 3 
7.1 ± 1.3 
8.0 ±1.6 
12.1 ± 3.9 
6.3 ± 1.1 
5.9 ± 1.7 
9.9 ± 3.7 
 13.0 ± 3.5 
18.7 ± 5.4 
19.5 ± 11.5 
1.0 ± 0.4 
1.2 ± 0.4 
2.3 ± 2.1 
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Fig. 8: General side effects after Medication and “Placebo” intake 
General psychological and medical indispositions were analyzed with the GASE after Medication (a) and “Pla-
cebo” intake, respectively (b). Val/Val homozygote carriers experienced significantly more general psychologi-
cal and medical indispositions after four medication intakes (a) and also showed the strongest nocebo re-
sponse, measured by most reported side effects after “Placebo” intake (b). Data were analyzed with univariate 
ANOVAs. In case of significant F tests, these were followed by Bonferroni post hoc tests. Bars represent 
mean ± SEM; *p<0.05, **p<0.01 
In parallel with the findings of increased perceived general side effects in Val/Val 
homozygote carriers, ANOVAs showed significant differences for CsA-specific 
side effects (F=11.9; p<0.001) with significantly more side effects reported in 
Val/Val and Met/Met groups than compared with the Val/Met group after Medica-
tion intake. Post hoc analysis showed a significant difference between Val/Val and 
Val/Met, p<0.001, as well as Val/Val and Met/Met, p<0.05 (Figure 9a). Even more 
noticeable differences in reported CsA-specific side effects between individuals of 
the three genotype groups were observed during “Placebo” treatment (F=13.1; 
p<0.001) with the most pronounced side effects reported from the Val/Val homo-
zygote carriers compared to the other two groups. Post hoc analysis showed a 
significant difference between Val/Val and Val/Met (p<0.001) as well as Val/Val 
and Met/Met (p<0.01). Remarkably, after fourteen intakes of “Placebo” capsules, 
the reported CsA-specific side effects were twice as high for the Val/Val homozy-
gote carriers when compared to four intakes of CsA during Medication (Figure 9b). 
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Fig. 9: CsA-specific side effects after Medication and “Placebo” intake 
Reported CsA-specific side effects after Medication (a) and “Placebo” intake, respectively (b). After Medication 
intake, significantly higher CsA-specific side effects were reported by Val/Val homozygote carriers (a). This 
difference was even more pronounced after fourteen “Placebo” intakes (b). Data were analyzed using univari-
ate ANOVA. In case of significant F tests, these were followed by Bonferroni post hoc tests. Bars represent 
mean ± SEM; *p<0.05, ***p<0.01 
3.2.2 Psychological trait and screening parameters 
Analysis of sociodemographic and psychological trait and screening variables with 
univariate ANOVAs showed no differences between all three genotypes for age, 
body mass index, physical activity, trait anxiety, as well as for the traits pessimism 
and optimism (Table 4).  
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Genotype Val/Val (n=19) Val/Met (n=34) Met/Met (n=9) 
Age (years) 
Body mass index (kg/m²) 
Physical activity (FFkA) 
Trait anxiety (STAI) 
LOT(R) Pessimism 
LOT(R) Optimism 
25.7 ± 1.1 
21.5 ± 1.9 
46.6 ± 8.7 
38.5 ± 1.8 
5.3 ± 2.8 
8.9 ± 0.5 
25.3 ± 0.6 
23.7 ± 0.5 
38.2 ± 4.2 
34.4 ± 1.3 
4.2 ± 0.4 
8.9 ± 0.4 
25.6 ± 1.3 
22.0 ± 2.9 
46.0 ± 11.2 
33.3 ± 2.6 
4.0 ± 0.7 
10.1 ± 0.5 
Tab. 4: Sociodemographic and psychological characteristics of the COMT genotype groups 
COMT genotype groups did not significantly differ in age, body mass index, physical activity, trait anxiety 
(STAI) scores, as well as within the traits pessimism and optimism LOT(R). Data were analyzed using univari-
ate ANOVA and are shown as mean ± SEM; all p>0.05 
However, significant differences between allele carriers of the COMT Val158Met 
polymorphism and four of six subscales of the beliefs about medicines question-
naire (BMQ) were found, in which prescribed medication for personal use 
(BMQ_specific), as well as beliefs about medicines in general (BMQ_general) are 
rated. Individuals with the Val/Val genotype reported more negative beliefs about 
medicines, judging the intake of medicines as a potential danger, having concerns 
about side effects, as well as accumulated long-term effects. They were signifi-
cantly more convinced that medication harms them in general (BMQ_general 
harm; F=4.2; p<0.05; Post hoc analysis showed a significant difference between 
Val/Val and Val/Met (p<0.05)) and they react more sensitive towards their effects 
(BMQ_sensitive soma; F=13.1; p<0.001; Post hoc analysis showed a significant 
difference between Val/Val and Val/Met (p<0.001), as well as Val/Val and Met/Met 
(p<0.001)). They also view themselves as significantly more dependent on medi-
cation (BMQ_specific necessity; F=5.6; p<0.01; Post hoc analysis showed a signif-
icant difference between Val/Val and Val/Met (p<0.05), as well as Val/Val and 
Met/Met (p<0.05)) and at the same time were more concerned about their side 
effects and feeling uneasy when taking them (BMQ_specific concerns; F=6.3; 
p<0.01; Post hoc analysis showed a significant difference between Val/Val and 
Val/Met (p<0.05), as well as Val/Val and Met/Met (p<0.01)). No differences were 
found in the scales BMQ_general overuse, which assess the perception that doc-
tors prescribe medicines too much and within the BMQ_general benefit, which 
measures the belief that a beneficial treatment can be achieved through medica-
tion.  
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In addition, the Val/Val homozygote carriers obtained significantly higher scores 
compared to the Val/Met and Met/Met carriers in the SSAS, measuring a disposi-
tion to identify natural occurring somatic and visceral sensations as being very 
strong, unpleasant and harmful (F=8.8, p<0.001). Post hoc analysis showed a sig-
nificant difference between participants of the genotypes Val/Val and Val/Met 
(p<0.001), as well as Val/Val and Met/Met (p<0.01) (Table 5). 
Genotype Val/Val (n=19) Val/Met (n=34) Met/Met (n=9) 
SSAS  
BMQ_general harm  
BMQ_general overuse  
BMQ_general benefit 
BMQ_sensitive soma  
BMQ_specific necessity  
BMQ_specific concerns 
29.4 ± 1.3 ** 
11.0 ± 0.7 * 
14.1 ± 0.7 
15.7 ± 0.6 
11.0 ± 0.8 *** 
9.2 ± 0.6 * 
12.1 ± 1.1 ** 
24.3 ± 0.8 
8.8 ± 0.5 
12.9 ± 0.5 
16.0 ± 0.4 
7.4 ± 0.4 
7.2 ± 0.4 
9.1 ± 0.6 
22.9 ± 1.3 
10.6 ± 0.7 
13.7 ± 0.8 
16.0 ± 0.7 
6.2 ± 0.5 
6.8 ± 0.5 
7.4 ± 0.7 
Tab. 5: Differences in the somatosensory amplification scale (SSAS) and four subscales of the 
beliefs about medicines questionnaire (BMQ) depending on the COMT genotype group 
SSAS, BMQ_general harm, BMQ_general overuse, BMQ_general benefit, BMQ_sensitive soma, 
BMQ_specific necessity and BMQ_specific concerns were compared between all COMT genotype groups. 
The significantly highest scores in the SSAS and four of the BMQ subscales (BMQ_general harm, 
BMQ_sensitive soma, BMQ_specific necessity and BMQ_specific concerns) were reported by carriers of the 
Val/Val homozygote, indicating a significantly higher belief that medication will harm in general and a higher 
sensitivity to bodily sensations, as well as more concerns about prescribed medication based on beliefs about 
the danger of dependence and long-term toxicity and the disruptive effects of medication. However, the three 
genotype groups did not differ in the two subscales BMQ_ general overuse and BMQ_ general benefit. Data 
were analyzed using univariate ANOVA. In case of significant F tests, these were followed by Bonferroni post 
hoc tests. Data are shown as mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 
The scores of the depression scale of the Hospital Anxiety and Depression Scale 
(HADS-D) revealed values within normal range for all participants (3.5 ± 0.3). 
3.2.3 Genetic and psychological variables and their influence on general 
and CsA-specific side effects 
The increased sensitivity of perceived general and CsA-specific side effects after 
Medication as well as “Placebo” treatment in Val/Val homozygote carriers is paral-
leled by significantly higher values within the SSAS and the four subscales of the 
BMQ (Table 5). In a subsequent step, the association of general as well as CsA-
specific side effects with a higher somatization tendency was tested. Pearson cor-
relations between the trait somatosensory amplification (SSAS) and the specific 
and general side effects were calculated. These correlations were significant for 
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somatosensory amplification and the specific side effects after Medication (r=.36; 
p<0.01) and “Placebo” intake (r=.41; p<0.001), as well as for the three time points, 
when the GASE was measured (Baseline: r=.47, p<0.001; after Medication intake: 
r=.54; p<0.001; after “Placebo” intake: r=.27; p<0.05). 
After showing a significant association between specific and general side effects 
and a higher somatization tendency, Pearson correlations between the trait soma-
tosensory amplification (SSAS) of the three respective genotypes and the specific 
and general side effects were analyzed (Table 6). No correlations were observed 
between SSAS scores of the Met/Met genotype and CsA-specific and general side 
effects. In contrast, SSAS scores were positively correlated with CsA-specific and 
general side effects in the Val/Val genotype during Medication intake but not dur-
ing “Placebo” treatment. In the Val/Met group, somatosensory amplification and 
CsA-specific side effects were also significantly correlated during Medication. 
Tab. 6: Pearson correlations between SSAS of the three COMT genotype groups and CsA-
specific and general side effects during the Medication and “Placebo” phase 
SSAS scores of the Met/Met genotype and CsA-specific and general side effects did not correlate. One signif-
icant correlation was measured for the Val/Met genotype between SSAS and CsA-specific side effects after 
Medication intake and two significant correlations for the Val/Val genotype between SSAS and CsA-specific as 
well as general side effects after Medication intake. Data are shown as Pearson correlations; *p<0.05, 
**p<0.01 
3.2.4 Manipulation of expectation 
Participants of all three groups estimated that after the first week, 62% of capsules 
contained CsA; after the first five capsules of placebo pills that estimation de-
creased to 38% and after the following five placebo intakes, lower to 34%. After 
the last four placebo intakes the estimation was 33% and the only observed group 
difference was that the Val/Val group estimated the amount of capsules containing 
CsA at 48%, whereas the Met/Met group thought only 26% and the Val/Met group 
27% of the pills contained the drug (F=3.6; p<0.05; Post hoc analysis showed a 
significant difference between Val/Val and Val/Met (p<0.05)) (Figure 10). Individu-
Medication  “Placebo” 
SSAS scores 
of Genotype  
CsA-specific 
side effects 
General side 
effects (GASE) 
 CsA-specific 
side effects 
General side 
effects (GASE) 
Val/Val (n=19) 
Val/Met (n=34) 
Met/Met (n=9) 
r=.52,  p<0.05 * 
r=-.38, p<0.05 * 
r=.08,  n.s. 
r=.67, p<0.01 ** 
r=.16, n.s. 
r=-.09, n.s. 
 r=.31, n.s. 
r=.01, n.s. 
r=.13, n.s. 
r=.16, n.s. 
r=.18, n.s. 
r=.30, n.s. 
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als of the Val/Val homozygote group estimated on the first day before taking any 
capsules that the chance of experiencing side effects would be 28%, whereas the 
Val/Met group thought it would be 20% and the Met/Met individuals rated the 
chance to be 11%. Although the Val/Val group had on average the highest expec-
tation to experience side effects, this estimation was not significantly higher com-
pared to the ratings of the other two groups (F=1.9; n.s.). 
 
Fig. 10: Estimation of percentage of ingested pills that contained CsA 
Subjects were told before each pill intake, that the chance of receiving CsA was always 50%. They were given 
visual analogue scales from 0 to 100 percent, in order to estimate the percentage of ingested pills that con-
tained CsA after every four to five pill intakes. Individuals with the Val/Val genotype always rated the amount 
of ingested CsA capsules higher than the other two genotype groups. This difference in rating was only signifi-
cant after the last four “Placebo” intakes. Data were analyzed with multivariate ANOVAs. In case of significant 
F tests, these were followed by Bonferroni post hoc tests. Line charts represent mean ± SEM; *p<0.05 
3.2.5 CsA levels, immunological and neuroendocrine parameters  
CsA levels were determined two hours after the last of four CsA intakes (10 am; 
peak level). After the Medication phase, CsA concentrations were significantly in-
creased in all three genotype groups without significant differences between 
groups. Post hoc tests revealed significant time effects from Pre I to Post I for all 
three genotype groups (Val/Val: t=-21.0, p<0.000; Met/Met: t=-11.9, p<0.000; 
Val/Met: t=-18.0, p<0.000) (Table 7). After treatment with subtherapeutic CsA dos-
es, marginal CsA concentrations could be detected in peripheral blood with no dif-
ferences between groups. Post hoc tests revealed significant time effects for all 
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three genotype groups when the CsA levels of Pre II were compared to Post II 
(Val/Val: t=-4.9, p<0.001; Met/Met: t=-4.1, p<0.001; Val/Met: t=-4.4, p<0.001) (Ta-
ble 7). 
These results are in accordance with the immune parameters, which were as-
sessed to measure the influence of the CsA effect and to ensure no differences 
between the allele carriers of the COMT Val158Met polymorphism. The IL-2 protein 
concentrations, IL-2 mRNA expression and the percentage of proliferating CD4+ T 
cells did not differ between the three groups during Medication and “Placebo” in-
take. However, after four CsA intakes, all these immune parameters were signifi-
cantly suppressed. Post hoc tests revealed significant time effects from Pre I to 
Post I for the IL-2 protein concentrations (Val/Val: t=4.2, p<0.001; Met/Met: t=5.1; 
p<0.001; Val/Met: t=5.6; p<0.001), the IL-2 mRNA expression (Val/Val: t=5.2; 
p<0.001; Met/Met: t=5.0; p<0.01; Val/Met: t=7.4; p<0.001) and the percentage of 
proliferating CD4+ T cells (Val/Val: t=8.5; p<0.001; Met/Met: t=4.0; p<0.01; Val/Met: 
t=14.1; p<0.001) (Table 7). Additionally, the amount of circulating CD3+, 
CD3+CD4+ and CD3+CD8+ cells were determined, using multivariate ANOVAs. 
There were no differences detected in all three groups (Table 7).  
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 Group Medication   “Placebo” 
  Pre I Post I Pre II Post II 
CsA levels in 
whole blood 
(ng/ml) 
Val/Val n.d. 1315.4 ± 61.4 t*** 
 
n.d. 62.1 ± 7.6 t*** 
Val/Met n.d. 1209.9 ± 65.9 t***  n.d. 48.5 ± 5.3 t*** 
Met/Met n.d. 1340.2 ± 110.3 t***  n.d. 49.9 ± 9.4 t*** 
       
IL-2 in culture 
supernatant 
(pg/ml) 
Val/Val 375.4 ± 61.0 160.4 ± 23.9 t***  395.4 ± 61.0 393.5 ± 60.3 
Val/Met 393.4 ± 63.6 127.4 ± 19.9 t***  375.9 ± 54.0 402.8 ± 59.6 
Met/Met 333.4 ± 68.2 86.8 ± 16.3 t***  398.6 ± 115.3 300.0 ± 103.8 
       
IL-2 mRNA 
(fg/µg total RNA) 
Val/Val 183.1 ± 31.4 45.3 ± 9.7 t***  194.7 ± 23.6 167.5 ± 26.5 
Val/Met 222.2 ± 24.7 60.1 ± 8.4 t***  224.1 ± 21.5 201.2 ± 19.3 
Met/Met 160.4 ± 31.0 46.6 ± 12.8 t**  170.9 ± 28.6 147.1 ± 16.3 
       
Proliferation 
(% proliferating 
CD4+T cells) 
Val/Val 26.1 ± 1.9 12.6 ± 1.2 t***  25.7 ± 2.3 23.6 ± 2.3 
Val/Met 26.3 ± 1.2 12.7 ± 0.8 t***  27.8 ± 1.8 25.6 ± 1.7 
Met/Met 32.0 ± 3.7 16.9 ± 2.3 t**  31.7 ± 3.2 32.1 ± 3.3 
       
CD3+ cells 
(cells/µl) 
Val/Val 3023.7 ± 96.4 3037.9 ± 107.4  2960.8 ± 125.3 2978.1 ± 96.5 
Val/Met 3131.1 ± 77.6 3249.1 ± 79.5  2940.1 ± 101.3 3009.6 ± 72.2 
Met/Met 3053.7 ± 155.6 3185.2 ± 144.4  2965.7 ± 172.0 3127.8 ± 174.4 
       
CD3+CD4+ cells 
(cells/µl) 
Val/Val 1728.5 ± 78.4 1772.0 ± 86.7  1662.3 ± 78.7 1724.1 ± 58.9 
Val/Met 1870.0 ± 77.4 2014.0 ± 76.5  1756.0 ± 79.5 1808.7 ± 60.0 
Met/Met 1808.9 ± 91.8 2027.0 ± 128.3  1778.0 ± 113.7 1877.0 ± 135.5 
       
CD3+CD8+ cells 
(cells/µl) 
Val/Val 1295.2 ± 96.1 902.3 ± 31.9  1298.4 ± 109.0 2003.5 ± 200.4 
Val/Met 1227.8 ± 79.4 965.0 ± 23.6  1180.1 ± 63.5 1954.1 ± 163.4 
Met/Met 1244.7 ± 150.5 946.0 ± 42.9  1003.3 ± 152.2 1869.7 ± 351.5 
Tab. 7: CsA levels and immunological parameters during Medication and “Placebo” intake  
CsA treatment during Medication significantly increased CsA serum levels and significantly suppressed IL-2 
protein concentrations, IL-2 mRNA expression and the percentage of proliferating CD4+ T cells in all COMT 
genotype groups. However, CsA treatment did not affect CD3+, CD3+CD4+ and CD3+CD8+cells in all groups. 
During the “Placebo” condition, treatment with subtherapeutical doses of CsA slightly increased CsA levels in 
Val/Val, Val/Met as well as Met/Met allele carriers; however it did not affect immune parameters or the circulat-
ing CD3+, CD3+CD4+ and CD3+CD8+cells in these groups. CsA levels and immune parameters were analyzed 
with multivariate ANOVAs (t= time effect; n.d= not detectable, <25 ng/ml). In case of significant F tests, these 
were followed by Bonferroni post hoc tests. Data are shown as mean ± SEM; **p<0.01 ***p<0.001 
In order to exclude any effects due to the activation of the HPA-axis or any in-
creased physical activation that could have influenced the perception of side ef-
fects, catecholamines (adrenaline, noradrenaline) and cortisol were measured be-
fore and after Medication and “Placebo” intake, using multivariate ANOVAs. There 
were no differences detected in all three groups (Figure 11, 12). 
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Fig. 11: Adrenaline and noradrenaline concentration in plasma before and after Medication and 
“Placebo” intake 
Participants of all three genotype groups did not differ in either adrenaline or noradrenaline concentration in 
plasma at all measured time points. Data were analyzed with multivariate ANOVAs. Line charts represent 
mean ± SEM; all p>0.05 
 
Fig. 12: Cortisol concentration in plasma before and after Medication and “Placebo” intake 
Individuals of all three genotype groups did not differ in cortisol concentration in plasma at all measured time 
points. Data were analyzed with multivariate ANOVAs. Line charts represent mean ± SEM; all p>0.05 
Lastly, cardiovascular parameters (systolic and diastolic blood pressure, heart 
rate) were measured before and after Medication and “Placebo” intake, in order to 
identify any side effects caused by CsA intake (Post I) or any physical arousal dur-
ing study participation (Pre I – Post II), using multivariate ANOVAs. There were no 
differences detected in any of the three groups (Figure 13, 14). 
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Fig. 13: Systolic and diastolic blood pressure before and after Medication and “Placebo” intake 
Participants of all three genotype groups did not differ in systolic and diastolic blood pressure at all measured 
time points. Data were analyzed with multivariate ANOVAs. Line charts represent mean ± SEM; all p>0.05 
 
Fig. 14: Heart rate before and after Medication and “Placebo” intake 
Participants of all three genotype groups did not differ in heart rate at all measured time points. Data were 
analyzed with multivariate ANOVAs. Line charts represent mean ± SEM; all p>0.05 
Thus, the significantly highest reported specific and general treatment side effects 
in Val/Val allele carriers during Medication and “Placebo” intake is most likely not 
due to increased or decreased physiological responses to the treatments. Togeth-
er, these data suggest that individuals of the Val/Val genotype have a higher so-
matosensory sensibility, more negative beliefs about medicines and experience 
more specific and general side effects after Medication and “Placebo” intake. 
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4 Discussion 
4.1 Somatosensory amplification, beliefs about medicines and the COMT 
Val158Met polymorphism as predictors of nocebo responses 
Finding psychological and biological variables that can predict nocebo responding 
within medical treatment contexts is of high value, as nocebo effects have been 
shown to contribute to decreases of drug efficacy and increases of side effects. 
Furthermore, the recognition of placebo and nocebo responders within drug test-
ing trials will be invaluable for estimating the real drug effects, as placebo re-
sponders may contribute to an underestimation of drug effects, whereas nocebo 
responders may lead to an overestimation of adverse medical side effects.  
Only few psychological predictor variables have been identified, such as soma-
tosensory amplification and the beliefs about medicines (Davis et al., 1995; 
Nestoriuc et al., 2010), whereas biological and/or genetic predictor variables are to 
this date lacking. However, gene polymorphisms, for example in the COMT gene, 
have recently been linked to placebo responding, in which individuals with the 
Met/Met genotype of the COMT Val158Met polymorphism have shown the strong-
est placebo response (Hall et al., 2012). Therefore, the experiment underlying this 
thesis sought to identify psychological and genetic predictor variables of nocebo 
responses, with the aim being to minimize nocebo effects and to increase medical 
treatment benefits for patients. 
In order to identify nocebo predictor variables, an established design of a study 
program on behavioral conditioning of immune functions was utilized (Albring et 
al., 2014). The unique advantage of this design is the ability to analyze intra-
individual nocebo responses, after the intake of the immunosuppressive drug CsA 
during the acquisition phase as well as after placebo intake during the evocation 
phase. Reported CsA-specific and general side effects during Medication and 
“Placebo” intake were analyzed in relation to the respective homocygotic (Val/Val; 
Met/Met) or heterocygotic (Val/Met) genotype of the COMT Val158Met polymor-
phism, as well as the degree of somatosensory amplification and negative beliefs 
about medicines.  
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This experiment showed for the first time, that significantly more CsA-specific as 
well as general side effects were experienced by individuals with the Val variant 
during medication and “Placebo” intake. In addition, homocygotic Val/Val carriers 
showed a significantly higher disposition to identify naturally occurring somatic and 
visceral sensations as being harmful, unpleasant, and very strong, which was 
measured with the SSAS. They also reported more negative beliefs about medi-
cines, judging the intake of medicines as a potential danger, having concerns 
about side effects, as well as accumulated long-term effects, which were meas-
ured with the BMQ. Numerous studies have associated more negative beliefs 
about medicines with lower medical treatment adherence (reviewed in Nestoriuc et 
al., 2010). No differences between the three genotype groups were found in the 
scales BMQ_general overuse, which assess the perception that doctors prescribe 
medicines too much and within the BMQ_general benefit, which measures the be-
lief that a beneficial treatment can be achieved through medicines. These sub-
scales assess the behavior of doctors and positive attitudes towards medicines 
and are not related to the higher negative belief about medicines reported from 
individuals with the Val variant.  
The differences in nocebo responses were not due to a range of possible interfer-
ing variables, as participants did not differ in sociodemographic and psychological 
trait variables, such as pessimism, trait anxiety and physical characteristics (physi-
cal activity, body mass index), which could have affected an increased experience 
of side effects. Differences in cardiovascular or neuroendocrine parameters 
(adrenaline, noradrenaline, cortisol plasma levels) were also not responsible, 
which could have been indicators of an increased stress reaction to the experi-
mental procedure or medication intake. Moreover, CsA levels in whole blood were 
continuously surveyed and no increase in blood pressure, a side effect of CsA 
treatment (Mihatsch et al., 1989), was observed. The CsA levels were washed out 
after the five-day break and were therefore not responsible for continuously re-
ported side effects when “Placebos” were taken. As an indicator of the immuno-
suppressive effects of CsA, immunological parameters (IL-2 production, IL-2 
mRNA expression, proliferation rate of CD4+ T cells, CD3+, CD3+CD4+ and 
CD3+CD8+ cells) were monitored with no difference noted between the three geno-
type groups, which could have explained CsA-specific and general side effects.  
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Together, these data suggest that COMT Val158Met, specifically the Val/Val geno-
type, higher degrees of somatosensory amplification and more negative beliefs 
about medicines are potential psychological and genetic predictor variables for 
nocebo responses. This is primarily true for the specific model employed here, in 
which healthy male subjects received a short-term treatment during the Medication 
period with an immunosuppressive drug; the calcineurin inhibitor CsA. Whether 
and to what extent this is a generalizable phenomenon and transferable to other 
drugs and/or patient populations (Furmark et al., 2008; Hall et al., 2012; Leuchter 
et al., 2009), needs to be investigated. Nevertheless, somatosensory amplification 
was associated with increased side effect reporting after the intake of placebos 
and antidepressants (Davis et al., 1995) and negative beliefs about arthritis medi-
cation predicted side effect occurrence within patients after taking them (Nestoriuc 
et al., 2010). The COMT polymorphism predicted placebo responses in patients 
with irritable bowel syndrome and depression (Hall et al., 2012; Leuchter et al., 
2009). These observations argue for a role of COMT, somatosensory amplification 
and beliefs about medicines in nocebo responses; also for other physiological sys-
tems and diseases. 
4.2 CsA-specific and general side effects 
The reason for more reported CsA-specific and general side effects from homo-
cygotic Val/Val allele carriers in this study remains unclear. The Val form catabo-
lizes dopamine three to four-times more effective than the Met form (Lachman et 
al., 1996), consequently leading to significantly lower concentrations of prefrontal 
dopamine in Val/Val carriers compared to Met/Met carriers. This different 
availability of prefrontal dopamine seems to affect processes associated with the 
nocebo effect, such as pain and memory function (reviewed in Hall et al., 2012) in 
general, but also led to a more pronounced placebo response in Met/Met allele 
carrying patients with irritable bowel syndrome (Hall et al., 2012). A possible rela-
tionship between a smaller amount of available dopamine in the prefrontal cortex 
(Val/Val individuals) and a more pronounced nocebo response needs to be inves-
tigated in future studies. 
Study participants with the Val variant reported 50% more CsA-specific side ef-
fects during the “Placebo” treatment compared to the intake of the drug CsA dur-
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ing Medication, which were solely explained by the COMT polymorphism as a co-
variate. This increase may be related to the longer time frame during the “Placebo” 
phase, where participants were continuously reminded every twelve hours, by the 
investigators, of the four CsA-specific side effects. Studies showed that the more 
information is given about potential side effects, the more they develop (Wise et 
al., 2009). An increase of side effects from the Medication to the “Placebo” phase 
was not found within general side effects. This may be due to more general psy-
chological and physical indispositions measured with the GASE, such as deject-
edness, back pain, palpitation, irritability and sexual problems. Furthermore, the 
GASE was only filled out after every seven days and investigators did not verbally 
inform individuals about these general side effects.  
Val/Val individuals had significantly more general symptoms measured with the 
GASE one week before study entry (GASE_Baseline) and patients with baseline 
somatic symptoms, have been shown to experience more adverse effects after 
medical treatments (Papakostas et al., 2004). However, more general side effects 
at Baseline did not predict general side effects at Pre II and Post II. Here, the so-
matosensory amplification scale had a significant effect on the experience of gen-
eral side effects as a covariate. The increased somatosensory awareness, within 
the Val/Val group may have led to an attribution of already existing symptoms to 
the taken medication.  
The number of valine alleles in COMT Val158Met was linearly related to the amount 
of reported general side effects at Baseline, Pre II and Post II, where individuals 
with the Val variant reported most side effects; the Val/Met variant intermediate 
and the Met variant reported the fewest. This additive effect of the COMT geno-
type was not shown for the CsA-specific side effects at Post I and Post II, where 
the Val/Met group reported more CsA-specific side effects than the Met/Met group, 
although this was not statistically significant. This may be due to the small sample 
size and to the differently measured side effects and requires further investigation. 
4.3 Expectations and the prevalence of side effects  
Participants of this study equally believed the cover story of this experiment, that 
the probability of receiving CsA was always 50% during three of four (after four 
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CsA and after five and ten placebo intakes) estimation ratings of pills containing 
CsA. There was a significant difference between Val/Val and Val/Met individuals 
only after the last four placebo intakes, where Val/Val individuals thought that 48% 
of these capsules contained CsA, whereas Val/Met individuals estimated that 27% 
contained the drug. Remarkably, participants had the highest statistically signifi-
cant estimation of 62% of pills containing CsA after the Medication phase com-
pared to the other three time points, during the “Placebo” phase, where the esti-
mation decreased from 38% to 34% and lastly to 33% (section 3.2.4). Neverthe-
less, the reported CsA-specific side effects increased by 50% for carriers of the 
Val/Val homozygote during “Placebo”. It appears likely that more negative beliefs 
about medicines and a higher somatosensory amplification may have led to the 
increased experience of side effects, instead of the expected amount of taken 
medication. 
In this study a control group (n=15) was included, which only received placebos 
throughout the whole study. This group serves as a control to rule out that the re-
ported side effects during the “Placebo” phase are based on the previous intake of 
CsA, which could have induced expectation and classical conditioning of side ef-
fects. Subjects of the control group also reported CsA-specific and general side 
effects during the Medication phase, but were not included for further genotype 
analysis, as these were significantly less compared to the other three experimental 
groups (groups 1-3), which received CsA. However, after 14 placebo intakes there 
was no difference in reported CsA-specific and general side effects. Therefore, the 
encounter with the drug CsA during the Medication phase did not appear to influ-
ence the reported side effects during the “Placebo” phase. These are rather due to 
the identified psychological and genetic variables within this experiment. This is in 
line with a recent finding, where the expectation of receiving CsA, although place-
bo capsules were taken, caused the experience of CsA-specific side effects 
(Wendt et al., forthcoming). 
4.4 Limitations of this study 
There are a few limitations within this study. Firstly, the findings are limited due to 
the small number of young and healthy male study subjects and have to be thus 
interpreted with caution. In the future, female participants should be included, as 
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they have been shown to report more nocebo effects within various experiments 
(Lorber et al., 2007; Ströhle, 2000). However, these effects may be partly due to 
the fact that males report less adverse effects to female experimenters (Flaten et 
al., 2006) and within this study, 80% of the investigators were females. The validity 
of the identified predictor variables need to be further tested within a patient popu-
lation that had frequent encounters with medical treatments and who may also 
display higher values of somatosensory amplification and have more negative be-
liefs about medicines. 
Additionally, the information material and systematic procedure of requesting side 
effects could have led to an increased reported amount. Participants received in-
formation leaflets about CsA-specific side effects before study entry and were in-
formed every twelve hours about common CsA-specific side effects. Numerous 
studies measured increased reported side effects within informed individuals com-
pared to uninformed individuals (Lang et al., 2005; Varelmann et al., 2010; Wise et 
al., 2009). In addition, they received questionnaires for CsA-specific and general 
side effects (GASE), which may have contributed to increased side effect reporting 
as well. This was shown in studies which measured more reported side effects 
from individuals which were systematically asked or filled out standardized ques-
tionnaires about side effects compared to those which freely reported them (Rief et 
al., 2006). 
Another limitation to consider is that two of the measured CsA-specific side effects 
can be defined as unspecific, such as fatigue and discomfort in the intestine and 
stomach and may have occurred independently from the experiment. Such symp-
toms also develop in individuals, which do not take any medication (Reidenberg 
and Lowenthal, 1968). Therefore, in future studies a “no treatment control group” 
should be included which only takes placebo capsules throughout the whole study 
in an open label procedure, in order to test if those symptoms occur independently 
from the experiment. 
Lastly, this study could not confirm previous identified psychological nocebo pre-
dictor variables, such as anxiety and pessimism (Elsenbruch et al., 2012; Geers et 
al., 2005). This is probably due to the large diversity within methods, experimental 
setup and physical systems studied of research projects analyzing the nocebo re-
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sponse. Furthermore, as outlined in section 1.3, multiple factors influence the 
nocebo response, which is why it is also not likely, that a single gene polymor-
phism alone can explain a complex behavioral response mechanism, such as the 
nocebo effect. Rather, further factors are involved, as was shown in a study, 
where the placebo response of individuals with the Met variant was enhanced 
through a positive doctor-patient relationship (Hall et al., 2012). Future investiga-
tions should nevertheless include identified predictor variables throughout different 
experiments and within the clinical context to test their reliability. However, if the 
mechanisms steering the nocebo response are carefully considered before a med-
ical treatment is initiated and individuals with an increased risk of developing 
nocebo effects, identified through psychological and biological variables, receive a 
personalized medical treatment, the nocebo response can be reduced.  
4.5 Utilizing associative learning processes and expectations to de-
crease nocebo responses 
The placebo effect has been shown to positively influence the outcome of medical 
treatments through associative learning processes and expectations (reviewed in 
Enck et al., 2013). Through associative learning models, it has been possible to 
reduce clinical medication dosages, while at the same time maintaining their ef-
fects on the physical system. This was achieved through partial reinforcement 
within behavioral conditioning paradigms, in which the full dose of medication is 
given during the acquisition phase paired with a CS. Subsequently, during the ev-
ocation phase the CS is given again, but the medication dosage is decreased by 
intermittently replacing it with a placebo (Doering and Rief, 2012). Similar effects 
can be achieved through reconsolidation models of behaviorally conditioned 
pharmacological responses, in which subtherapeutic medical dosages are given 
during the evocation phase (Albring et al., 2014). In addition, positive expectations 
of treatment outcomes have influenced invasive medical interventions in beneficial 
ways for patients undergoing cardiac and orthopaedic surgery and for patients with 
Parkinson’s disease receiving deep brain stimulation (reviewed in Enck et al., 
2013). 
Associative learning processes and expectations have demonstrated opposing 
effects for placebo and nocebo responses (Bingel et al., 2011; Varelmann et al., 
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2010), which can be utilized to prevent the development of nocebo responses be-
fore a medical treatment is initiated. Numerous studies have shown that through 
positive verbal information and observational learning, a placebo response can be 
elicited instead of a nocebo response (Bingel et al., 2011; Colloca et al., 2008; 
Varelmann et al., 2010). Additional factors inducing nocebo responses (section 
1.3) can also be preventatively modified, as psychological predictors of placebo 
and nocebo responses are often elicited and modified through environmental fac-
tors (Geers et al., 2005; Petrie et al., 2005). Symptoms and side effects may be 
the somatic manifestation of a negative affective state, stress or anxiety 
(Ferguson, 1993). These can be modified through a positive doctor-patient rela-
tionship, as this may activate neural mechanisms underlying the placebo re-
sponse. This has been shown in patients with irritable bowel syndrome, when the 
doctor switched from a technical and short to a warm and empathetic interaction, 
resulting in a placebo response increase from 42% to 82% (Kaptchuk et al., 2008). 
Informed consents and patient information leaflets usually include numerous pos-
sible side effects, which are given to the patient before the onset of a medical 
treatment (Colagiuri et al., 2012), although this has been shown to induce nocebo 
effects (Lang et al., 2005; Varelmann et al., 2010; Wise et al., 2009). They should 
rather include beneficial treatment information, so that positive expectations are 
developed. 
Besides minimizing factors that may induce nocebo responses, another approach 
is the identification of individuals with higher risk factors, to develop nocebo re-
sponses and offer them a personalized medical treatment. 
4.6 Future outlook: Personalized medical treatments 
Individuals with higher risks of developing nocebo responses could be identified 
conveniently and inexpensively through brief questionnaires, such as the SSAS 
and BMQ and/or the determination of the respective COMT genotype. These indi-
viduals may in turn receive a “personalized treatment”, instead of a common medi-
cal regimen. This can be achieved through the usage of a “contextualized in-
formed consent”, education about the nocebo effect and re-attribution techniques 
of physical symptoms.  
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The usage of a “contextualized informed consent” offers a compromise between 
the judicial need of informed consent and the prevention of nocebo effects at the 
same time. The information given to the patient is adjusted so that neither the 
transparency of the procedure nor the principle of nonmaleficence, are compro-
mised. Unspecific and harmless side effects are not mentioned; in order to avoid 
nocebo effects, whereas specific adverse effects are carefully explained so that 
the patient can decide if they want to take the drug (Wells and Kaptchuk, 2012). 
Nocebo education in the health care system has been neglected, as three quarters 
of health care professionals are unaware of the nocebo effect (Berthelot et al., 
2001). This can have negative implications, as the occurrence of side effects with-
in individuals participating in drug trials have shown to represent the expectations 
of the investigators in both drug and placebo groups (Amanzio et al., 2009). Pa-
tients unaware of the nocebo effect, receive information about it before a treatment 
is initiated and with their consent, information limited to possible mild and transient 
side effects is given (Miller and Colloca, 2011). 
The nocebo response may be partly due to the re-evaluation of already existing 
physical symptoms, common among healthy individuals. Various symptoms occur-
ring within the last three days of being questioned, have been reported by 73% of 
236 healthy individuals, who did not take any medication (Khosla et al., 1992). 
Therefore, the potential to attribute adverse effects to drugs or medical treatments, 
by misattributing already existing physical symptoms is large. Individuals with high 
scores within the SSAS, could receive re-attribution techniques, to learn to view 
somatic symptoms as naturally occurring, as well as techniques to reduce stressful 
reactions towards these symptoms.  
In conclusion, through minimizing factors that may induce nocebo responses, as 
well as through implementing personalized medical treatment regimens for indi-
viduals with higher risk factors in developing nocebo responses, medical treatment 
efficacy can be increased and the burden caused by side effects minimized for the 
patient’s benefit.  
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Summary 
Nocebo-induced side effects play a significant role in drug discontinuation in clini-
cal practice, thereby negatively affecting treatment efficacy as well as patient ad-
herence and compliance. Due to the large interindividual variability in nocebo re-
sponses, the goal of this thesis was to identify nocebo predictors in order to mini-
mize nocebo effects and increase medical treatment benefits for patients. Psycho-
logical predictors, such as beliefs about medicines and somatosensory amplifica-
tion have previously been linked to nocebo responses; however, to this date there 
are no known biological predictors. Recently, genetic polymorphisms in the cate-
chol-O-methyltransferase gene (COMT) Val158Met have been identified as poten-
tial biomarkers of placebo responses. 
Utilizing the unique model of behaviorally conditioned immunosuppressive effects, 
intra-individual nocebo responses of 62 healthy male subjects were analyzed after 
the intake of an immunosuppressive medication (CsA) and “Placebos”. Psycholog-
ical, immunological and neuroendocrine parameters were analyzed and CsA-
specific and general side effects were assessed before and after medication or 
“Placebo” intake. The three COMT genotypes were analyzed with respect to their 
experienced side effects. Significantly more CsA-specific as well as general side 
effects were reported from Val/Val carriers during medication and “Placebo” treat-
ment compared to the other genotype groups; and they had significantly higher 
scores in the somatosensory amplification scale (SSAS) and the BMQ (beliefs 
about medicine questionnaire). 
Together these data demonstrate potential psychological and genetic nocebo pre-
dictor variables. They may be utilized in decreasing adverse nocebo effects within 
medical contexts by implementing personal treatment regimens for individuals with 
a heightened risk of developing nocebo responses. 
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CaN calcineurin 
CCK cholecystokinin 
cDNA complementary deoxyribonucleic acid 
CNS central nervous system 
COMT catechol-O-methyltransferase 
CR conditioned response 
CS   conditioned stimulus   
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IC insular cortex 
IFN- interferon- 
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